Form 10Q

0001513162-17-000168.txt : 20170526 0001513162-17-000168.hdr.sgml : 20170526 20170526161520 ACCESSION NUMBER: 0001513162-17-000168 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20170430 FILED AS OF DATE: 20170526 DATE AS OF CHANGE: 20170526 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ITUS Corp CENTRAL INDEX KEY: 0000715446 STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794] IRS NUMBER: 112622630 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37492 FILM NUMBER: 17874135 BUSINESS ADDRESS: STREET 1: 12100 WILSHIRE BOULEVARD CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: 31044845200 MAIL ADDRESS: STREET 1: 12100 WILSHIRE BOULEVARD CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: COPYTELE INC DATE OF NAME CHANGE: 19920703 10-Q 1 form10q.htm FORM 10-Q Form 10Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2017

Commission file number 0-11254

ITUS Corporation

(Exact name of registrant as specified in its charter)

Delaware 11-2622630

(State or other jurisdiction of (I.R.S. Employer

incorporation or organization) Identification No.)

12100 Wilshire Boulevard, Suite 1275

Los Angeles, CA 90025

(Address of principal executive offices) (Zip Code)

(310) 484-5200

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes X No ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [ ] (Do not check if a smaller reporting company)		Smaller reporting company [X]
Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ____ No X

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

On May 25, 2017, the registrant had outstanding 15,120,239 shares of Common Stock, par value $.01 per share, which is the registrant’s only class of common stock.

TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements.

	Condensed Consolidated Balance Sheets as of April 30, 2017 (Unaudited) and October 31, 2016	3

	Condensed Consolidated Statements of Operations (Unaudited) for the six months ended April 30, 2017 and 2016	4

	Condensed Consolidated Statements of Operations (Unaudited) for the three months ended April 30, 2017 and 2016	5

	Condensed Consolidated Statement of Shareholders’ Equity (Unaudited) for the six months ended April 30 2017	6

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended April 30, 2017 and 2016	7

	Notes to Condensed Consolidated Financial Statements (Unaudited)	8

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations.	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	26

Item 4.	Controls and Procedures.	26

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings.	27

Item 1A.	Risk Factors.	27

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	27

Item 3.	Defaults Upon Senior Securities.	27

Item 4.	Mine Safety Disclosures.	27

Item 5.	Other Information.	27

Item 6.	Exhibits.	27

SIGNATURES		28

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

ITUS CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

April 30,
2017

October 31,

2016

ASSETS

Current assets:

Cash and cash equivalents

$

2,876,897

$

2,488,323

Short-term investments in certificates of deposit

2,250,000

750,000

Prepaid expenses and other current assets

64,647

162,069

Total current assets

5,191,544

3,400,392

Patents, net of accumulated amortization of $1,127,688 and $965,040, respectively

1,908,423

2,071,071

Property and equipment, net of accumulated depreciation of $68,228 and
    $46,950, respectively

149,487

156,644

Total assets

$

7,249,454

$

5,628,107

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued expenses

$

660,023

$

468,756

Secured debenture (Note 7)

3,000,000

-

Total current liabilities

3,660,023

468,756

Patent acquisition obligation

-

4,171,876

Total liabilities

3,660,023

4,640,632

Commitments and contingencies (Note 11)





Shareholders’ equity:

Preferred stock, par value $100 per share; 19,860 shares authorized; no
    shares issued or outstanding

-

-

Series A convertible preferred stock, par value $100 per share; 140 shares
    authorized; -0- and 140 shares issued and outstanding, respectively

-

14,000

Common stock, par value $.01 per share; 24,000,000 shares authorized;
   11,694,863 and 8,752,387 shares issued and outstanding, respectively

116,949

87,524

Additional paid-in capital

156,066,446

152,051,144

Accumulated deficit

(152,593,964)

(151,165,193)

Total shareholders’ equity

3,589,431

987,475

Total liabilities and shareholders’ equity

$

7,249,454

$

5,628,107

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ITUS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
	For the Six Months Ended April 30,
	For the Six Months Ended April 30,
	2017		2016
Revenue	$	-	$	-

Operating costs and expenses:
Litigation and licensing expenses		2,346		75,162
Amortization of patents		162,648		162,648
Research and development expenses (including non-cash stock option compensation expenses of $148,628 and $91,442, respectively)		882,754		850,910
Marketing, general and administrative expenses (including non-cash stock option compensation expenses of $303,028 and $238,307, respectively)		1,559,230		1,532,106
Total operating costs and expenses		2,606,978		2,620,826

Loss from operations		(2,606,978)		(2,620,826)

Gain on extinguishment of patent acquisition obligation (Note 6)		1,547,608		-

Interest expense		(371,026)		(250,881)

Interest income		1,625		6,724

Loss before income taxes		(1,428,771)		(2,864,983)

Provision for income taxes		-		-

Net loss		(1,428,771)		(2,864,983)

Deemed dividend to preferred stockholder (Note 7)		(2,008,775)		-

Net loss attributable to common stockholders	$	(3,437,546)	$	(2,864,983)

Net loss per common share:
Basic and diluted	$	(0.37)	$	(0.33)

Weighted average common shares outstanding:
Basic and diluted		9,236,351		8,731,489

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ITUS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	For the Three Months Ended April 30,
	For the Three Months Ended April 30,
	2017		2016
Revenue	$	-	$	-

Operating costs and expenses:
Litigation and licensing expenses		225		15,521
Amortization of patents		81,324		81,324
Research and development expenses (including non-cash stock option compensation expenses of $68,928 and $72,496, respectively)		431,124		392,589
Marketing, general and administrative expenses (including non-cash stock option compensation expenses of $122,991 and $144,758 respectively)		699,345		658,953
Total operating costs and expenses		1,212,018		1,148,387

Loss from operations		(1,212,018)		(1,148,387)

Gain on extinguishment of patent acquisition obligation (Note 6)		1,547,608		-

Interest expense		(175,727)		(126,980)

Interest income		626		3,473

Income (loss) before income taxes		160,489		(1,271,894)

Provision for income taxes		-		-

Net income (loss)	$	160,489	$	(1,271,894)


Net income (loss) per common share:
Basic	$	0.02	$	(0.15)
Diluted	$	0.02	$	(0.15)

Weighted average common shares outstanding:
Basic		9,734,171		8,736,024
Diluted		9,736,571		8,736,024

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ITUS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY FOR THE SIX MONTHS ENDED April 30, 2017 (UNAUDITED)
							Additional Paid-in Capital				Total Shareholders’ Equity
	Preferred Stock			Common Stock					Accumulated Deficit
	Shares	Par Value		Shares	Par Value				Accumulated Deficit

Balance, October 31, 2016	140	$	14,000	8,752,387	$	87,524	$	152,051,144	$	(151,165,193)	$	987,475

Stock option compensation to employees and directors	-		-	-		-		451,655		-		451,655

Common stock issued upon exercise of stock options	-		-	2,200		22		5,643		-		5,665

Common stock issued to consultants	-		-	3,463		35		17,776		-		17,811

Redemption of convertible preferred stock (Note 7)	(140)		(14,000)	-		-		(3,486,000)		-		(3,500,000)

Common stock issued to repay patent acquisition obligation (Note 6)	-		-	947,606		9,476		2,842,818		-		2,852,294

Common stock issued in shareholder rights offering	-		-	1,989,207		19,892		4,183,410		-		4,203,302

Net loss	-		-	-		-		-		(1,428,771)		(1,428,771)

Balance, April 30, 2017	-	$	-	11,694,863	$	116,949	$	156,066,446	$	(152,593,964)	$	3,589,431

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ITUS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
	For the six months ended April 30,
	For the six months ended April 30,
	2017		2016
Reconciliation of net loss to net cash used in operating activities:
Net loss	$	(1,428,771)	$	(2,864,983)
Stock option compensation to employees and directors		451,655		329,749
Common stock issued to consultants		17,811		11,361
Depreciation of property and equipment		21,278		13,881
Amortization of patents		162,648		162,648
Accretion of interest on patent acquisition obligations to interest expense		228,026		250,881
Accrued interest on secured debenture		30,000		-
Gain on extinguishment of patent acquisition obligation		(1,547,608)		-
Common stock issued to acquire patent license		-		11,800
Change in operating assets and liabilities:
Prepaid expenses and other current assets		97,422		87,496
Accounts payable and accrued expenses		161,267		132,031
Royalties and contingent legal fees payable		-		(18,883)
Net cash used in operating activities		(1,806,272)		(1,884,019)

Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit		(2,250,000)		(1,550,000)
Proceeds from maturities of short-term investments in certificates of deposit		750,000		1,800,000
Payments for purchases of property and equipment		(14,121)		(141,110)
Net cash (used in) provided by investing activities		(1,514,121)		108,890

Cash flows from financing activities:
Redemption of convertible preferred stock		(500,000)		-
Proceeds from sale of common stock through a rights offering to shareholders		4,203,302		-
Proceeds from exercise of employee stock options		5,665		18,231
Net cash provided by financing activities		3,708,967		18,231

Net increase (decrease) in cash and cash equivalents		388,574		(1,756,898)
Cash and cash equivalents at beginning of period		2,488,323		4,369,219
Cash and cash equivalents at end of period	$	2,876,897	$	2,612,321

Supplemental disclosure of non-cash financing activities:
Redemption of Series A convertible preferred stock into secured debenture (Note 7)	$	(3,000,000)	$	-
Common stock issued to pay patent acquisition obligation (Note 6)	$	(4,399,902)	$	-

The accompanying notes are an integral part of these statements.

Table of Contents

ITUS CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. BUSINESS AND FUNDING

Description of Business

As used herein, “we,” “us,” “our,” the “Company” or “ITUS” means ITUS Corporation and its wholly-owned subsidiaries. From inception through October 2012, our primary operations involved the development of patented technologies in the areas of thin-film displays and encryption. Beginning in October of 2012 under the leadership of a new management team, we recapitalized the Company, changed the Company’s name and ticker symbol, relocated the Company’s headquarters, and modernized its systems. In July of 2015, the Company’s stock was accepted for listing and began trading on the NASDAQ Capital Market.

From October of 2015 through January of 2017, ITUS announced that we had demonstrated the efficacy of our CchekÔ early cancer detection platform with Breast Cancer, Lung Cancer Melanoma, Ovarian Cancer, Liver Cancer, Thyroid Cancer, Pancreatic Cancer, Appendiceal Cancer (cancer of the appendix), Uterine Cancer, Osteosarcoma (cancer of the bone), Leiomyosarcoma (cancer of the soft tissue), Liposarcoma (cancer of the connective tissue), Vulvar Cancer (cancer of the vulva), and Prostate Cancer, bringing the number of cancer types for which the efficacy of CchekÔ has been validated thus far to fifteen.

Over the next several quarters, we expect Cchek™ to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities in the area of encrypted audio/video conference calling. We do not expect these activities to be a significant part of the Company’s ongoing operations.

In the past, our revenue has been derived from technology licensing and the sale of patented technologies, including in connection with the settlement of litigation. In addition to Anixa, the Company may make investments in and form new companies to develop additional emerging technologies.

Table of Contents

Funding and Management’s Plans

During the six months ended April 30, 2017, cash used in operating activities was approximately $1,806,000. Net cash used by investing activities was approximately $1,514,000, which reflects the purchase of certificates of deposit totaling $2,250,000, offset by proceeds from the sale or maturity of certificates of deposit totaling $750,000 and the purchase of property and equipment of approximately $14,000. Cash provided by financing activities was approximately $3,709,000, representing net proceeds from the sale of shares of common stock to Company shareholders through a rights offering receiving proceeds of approximately $4,203,000 and the exercise of stock options, offset by the redemption of our Series A Convertible Preferred Stock (the “Series A Preferred”) of $500,000. As a result, our cash, cash equivalents and short-term investments at April 30, 2017 increased by approximately $1,889,000 to approximately $5,127,000 from approximately $3,238,000 at the end of fiscal year 2016.

Based on currently available information as of May 25, 2017, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows from operations will be sufficient to fund our activities and debt obligations for the next 12 months. However, our projections of future cash needs and cash flows may differ from actual results. To date, we have relied primarily upon cash from the public and private sale of equity and debt securities to generate the working capital needed to finance our operations. If current cash on hand, cash equivalents, short term investments and cash that may be generated from our business operations are insufficient to continue to operate our business and repay our indebtedness, we will be required to obtain more working capital. We may seek to obtain working capital through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible and as permitted pursuant to our existing indebtedness. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding, the sale of additional equity securities or convertible debt could result in dilution to our stockholders. Additionally, the sale of equity securities or issuance of debt securities may be subject to certain security holder approvals or may result in the downward adjustment of the exercise or conversion price of our outstanding securities. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, it could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations.

Subsequent Event

On May 16, 2017, the Company completed a registered public offering of 3,425,376 shares of common stock, generating net proceeds of approximately $3,214,000. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the potential payment of corporate debt.

Table of Contents

As of May 25, 2017, significant balance sheet amounts affected by this offering are approximately as follows:

Cash, cash equivalents and short term investments	$	8,104,000
Total assets	$	10,227,000
Total shareholders’ equity	$	6,567,000

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and footnotes required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended October 31, 2016, as reported by us in our Annual Report on Form 10-K. The October 31, 2016 consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (“US GAAP”). The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of April 30, 2017, and results of operations and cash flows for the interim periods represented. The results of operations for the six and three months ended April 30, 2017 are not necessarily indicative of the results to be expected for the entire year.

Revenue Recognition

Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed pursuant to the terms of the arrangement, (iii) amounts are fixed or determinable, and (iv) the collectability of amounts is reasonably assured.

Patent Licensing

In certain instances, our past revenue arrangements have provided for the payment of contractually determined fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we had no further obligations. As such, the earnings process was complete and revenue has been recognized upon the execution of the agreement, when collectability was reasonably assured, and when all other revenue recognition criteria were met.

Table of Contents

Intangible Assets

Our only identifiable intangible assets are patents and patent rights. We capitalize patent and patent rights acquisition costs and amortize the cost over the estimated economic useful life. We did not capitalize any patent acquisition costs during the six months ended April 30, 2017 and 2016. We recorded patent amortization expense of approximately $163,000 during each of the six month periods ended April 30, 2017 and 2016, respectively, and approximately $81,000 during each of the three month periods ended April 30, 2017 and 2016, respectively.

2. STOCK BASED COMPENSATION

The Company maintains stock equity incentive plans under which the Company grants non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants.

Stock Option Compensation Expense

The compensation cost for stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is recognized as an expense, on a straight-line basis, over the requisite service period (the vesting period of the stock option) which is one to ten years. We recorded stock-based compensation expense, related to stock options granted to employees and directors, of approximately $452,000 and $330,000 during the six months ended April 30, 2017 and 2016, respectively, and approximately $192,000 and $217,000 during the three months ended April 30, 2017 and 2016, respectively.

Stock Option Activity

During the six months ended April 30, 2017 and 2016, we granted options to purchase 106,000 shares and 545,000 shares of common stock, respectively, to employees and directors at exercise prices of $5.00 and $2.92 per share, respectively, pursuant to the ITUS Corporation 2010 Share Incentive Plan (the "2010 Share Plan”). During the six months ended April 30, 2017 and 2016, stock options to purchase 2,200 and 7,080 shares of common stock, respectively, were exercised with aggregate proceeds of approximately $6,000 and $18,000, respectively.

Stock Option Plans

As of April 30, 2017, we have two stock option plans: the ITUS Corporation 2003 Share Incentive Plan (the "2003 Share Plan") and the 2010 Share Plan, which were adopted by our Board of Directors on April 21, 2003 and July 14, 2010, respectively.

Table of Contents

The 2003 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to key employees, directors and consultants. In accordance with the provisions of the 2003 Share Plan, the plan terminated with respect to the ability to grant future options on April 21, 2013. Information regarding the 2003 Share Plan for the six months ended April 30, 2017 is as follows:

		Weighted Average Exercise Price Per Share
				Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2016	225,600	$	18.69
Exercised	(2,200)	$	2.58
Forfeited	(34,400)	$	17.85
Options Outstanding and exercisable at April 30, 2017	189,000	$	19.03	$	390

The following table summarizes information about stock options outstanding and exercisable under the 2003 Share Plan as of April 30, 2017:

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$1.79 - $7.75	39,000	1.32	$	2.92
$13.50 - $17.50	21,400	.45	$	16.46
$18.75 - $23.00	88,600	.37	$	22.13
$29.25	40,000	.31	$	29.25

The 2010 Share Plan provides for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to key employees, directors and consultants. As of April 30, 2017, the 2010 Share Plan had 764,000 shares available for future grants. Information regarding the 2010 Share Plan for the six months ended April 30, 2017 is as follows:

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2016	1,080,872	$	3.12
Granted	106,000	$	5.00
Options Outstanding at April 30, 2017	1,186,872	$	3.29	$	-
Options Exercisable at April 30, 2017	793,994	$	3.15	$	-

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2017:

	Options Outstanding				Options Exercisable
		Weighted Average Remaining Contractual Life (in years)				Weighted Average Remaining Contractual Life (in years)
								Weighted Average Exercise Price
				Weighted Average Exercise Price
Range of Exercise Prices	Number Outstanding				Number Exercisable
Range of Exercise Prices	Number Outstanding				Number Exercisable

$2.58 - $9.25	1,186,872	7.42	$	3.29	793,994	6.65	$	3.15

Table of Contents

In addition to options granted under the 2003 Share Plan and the 2010 Share Plan, the Board of Directors approved the grant of stock options to purchase 1,780,000 shares. Information regarding stock options outstanding that were not granted under the 2003 Plan or the 2010 Plan for the six months ended April 30, 2017 is as follows:

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2016	1,780,000	$	2.70
Options Outstanding and exercisable at April 30, 2017	1,780,000	$	2.70	$	-

The following table summarizes information about stock options outstanding and exercisable that were not granted under the 2003 Share Plan or the 2010 Share Plan as of April 30, 2017:

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$2.58 - $5.56	1,780,000	5.26	$	2.70

Stock Awards

We account for stock awards granted to employees and consultants based on the grant date market price of the underlying common stock. During the six months ended April 30, 2017 and 2016, we issued 3,463 shares and 3,701 shares, respectively, of common stock to consultants for services rendered. We recorded consulting expense for the six months ended April 30, 2017 and 2016 of approximately $18,000 and $11,000, respectively, for the shares of common stock issued to consultants.

3. FAIR VALUE MEASUREMENTS

US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:

Table of Contents

Level 1 - Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date.

Level 2 - Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.

Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset and liabilities.

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of April 30, 2017:

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	2,585,760	$	-	$	-	$	2,585,760
Certificates of deposit – Short-term investments		-		2,250,000		-		2,250,000
Total financial assets	$	2,585,760	$	2,250,000	$	-	$	4,835,760

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2016:

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	1,899,136	$	-	$	-	$	1,899,136
Certificates of deposit – Short-term investments		-		750,000		-		750,000
Total financial assets	$	1,899,136	$	750,000	$	-	$	2,649,136

The following table presents the hierarchy for our financial liabilities measured at fair value on the transaction date and then adjusted for the subsequent accretion of interest as of April 30, 2017:

	Level 1		Level 2		Level 3		Total

Patent acquisition obligation	$	-	$	-	$	-	$	-

Table of Contents

	Level 1		Level 2		Level 3		Total

Patent acquisition obligation	$	-	$	-	$	4,171,876	$	4,171,876

The following table sets forth the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

Patent acquisition obligation
Balance October 31, 2016	$	4,171,876
Accreted interest on patent obligation		228,026
Extinguishment of patent obligation		(4,399,902)
Balance April 30, 2017	$	-

Our non-financial assets that are measured on a non-recurring basis include our patents and property and equipment which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses, accounts payable and accrued expenses approximates their individual carrying amounts due to the short term nature of these measurements. Cash and cash equivalents are stated at carrying value which approximates fair value.

4. INVESTMENTS

At April 30, 2017 and October 31, 2016, we had certificates of deposit of $2,250,000 and $750,000, respectively, which were classified as short-term investments and reported at fair value.

5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expense consist of the following as of:

	April 30, 2017		October 31, 2016
	April 30, 2017		October 31, 2016
Accounts payable	$	448,353	$	373,224
Payroll and related expenses		59,497		49,901
Accrued interest on secured debenture		30,000		-
Accrued other		122,173		45,631
	$	660,023	$	468,756

6. PATENT ACQUISITION OBLIGATION

On March 27, 2017, the Company issued 947,606 shares of common stock to Meetrix Communications, Inc. (“Meetrix”) in satisfaction of the obligation owed by us to Meetrix pursuant to the terms of the Patent Acquisition Agreement, dated November 11, 2013 between the Company and Meetrix. The carrying value of the patent acquisition obligation at the date of extinguishment was approximately $4,400,000. The fair value of the shares of common stock issued to satisfy the obligation on the date of extinguishment was approximately $2,843,000, resulting in the recognition of a gain on the debt extinguishment of approximately $1,548,000.

Table of Contents

7. PREFERRED STOCK REDEMPTION

On November 11, 2016, the holder of all our outstanding Series A Preferred with an aggregate stated value of $3,500,000 exercised its right of redemption to receive such amount from proceeds from the sale of the Company’s equity securities. On December 6, 2016, we entered into an agreement with the holder of the Series A Preferred setting forth the terms under which such redemption would take place (the “Series A Redemption Terms”). Pursuant to the Series A Redemption Terms, on December 9, 2016 the holder of the Series A Preferred received (i) $500,000 in cash, (ii) a 12% secured debenture evidencing the remaining $3,000,000 amount to be redeemed, $1,000,000 of which is due on or before June 1, 2017 and the remainder of which is due November 11, 2017 (the “Redemption Debenture”), and (iii) a 5 year warrant to purchase 500,000 shares of the Company’s common stock at an exercise price equal to 10% below the thirty (30) day volume weighted average closing price of our common stock at closing (the “Redemption Warrant”). The Redemption Debenture is secured by a lien on the Company’s assets and prohibits the Company from incurring any senior indebtedness other than equipment financing in connection with the Company’s business.

The difference between the fair value of the consideration given to the holder of our Series A Preferred and the carrying value of the Series A Preferred represents a return to the preferred stockholder which is treated in a similar manner as that of dividends paid on preferred stock. In the redemption, the Series A Preferred holder received $500,000 in cash, the Redemption Debenture with a present value of approximately $2,999,000 and the Redemption Warrant with a fair value of approximately $2,801,000, determined using the Black Scholes pricing model, and waived the Series A Preferred’s conversion right with an intrinsic value of approximately $792,000, resulting in total consideration given to the Series A Preferred holder of approximately $5,508,000. The difference between the fair value of the consideration and the $3,500,000 carrying value of the Series A Preferred resulted in a deemed dividend to the Series A Preferred holder of approximately $2,008,000.

8. NET INCOME (LOSS) PER SHARE OF COMMON STOCK

Basic net income (loss) per common share (“Basic EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted net income (loss) per common share (“Diluted EPS”) is computed by dividing net income (loss) by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. The treasury stock method reduces the dilutive effect of potentially dilutive securities as it assumes that any cash proceeds (from the issuance of potentially dilutive securities) are used to buy back shares at the average share price during the period.

Diluted EPS for the six months ended April 30, 2017 and for the six and three months ended April 30, 2016 is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the six months ended April 30, 2017 were stock options to purchase 3,155,872 shares and warrants to purchase 837,400 shares and for the six and three months ended April 30, 2016 were stock options to purchase 3,138,472 shares, warrants to purchase 707,387 shares and preferred stock convertible into 739,958 shares.

Table of Contents

Dilutive EPS for the three months ended April 30, 2017 excluded stock options to purchase 3,153,472 shares and warrants to purchase 837,400 shares because their effect would be antidilutive. The following is a reconciliation between basic weighted average common shares outstanding and dilutive weighted average common shares outstanding for the three months ended April 30, 2017:

		For the Three Months Ended April 30, 2017
		For the Three Months Ended April 30, 2017
Basic weighted average common shares outstanding		9,734,171
Effect of stock options		2,400
Dilutive weighted average common shares outstanding		9,736,571

9. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers. This amendment updates addressing revenue from contracts with customers, which clarifies existing accounting literature relating to how and when a company recognizes revenue. Under the standard, a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. This standard update was effective for interim and annual reporting periods beginning after December 15, 2016, and were to be applied retrospectively or the cumulative effect as of the date of adoption, with early application not permitted. In July 2015, a one-year deferral of the effective date of the new guidance was approved. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is currently ongoing.

In August 2014, the FASB issued Accounting Standards Update 2014-15 (“ASU 2014-15”). This amendment requires management to assess an entity’s ability to continue as a going concern every reporting period including interim periods, and to provide related footnote disclosure in certain circumstances. Adoption of this standard is required for annual periods ending after December 15, 2016 and are to be applied retrospectively or the cumulative effect as of the date of adoption. The adoption of this amendment on November 1, 2016 did not have an impact on our consolidated financial statements and related disclosures.

In November 2015, the FASB issued Accounting Standards Update 2015-17 (“ASU 2015-17”) to simplify the presentation of deferred taxes. This amendment requires that all deferred tax assets and liabilities, along with any related valuation allowances, be classified as noncurrent on the balance sheet. Adoption of this standard is required for annual periods beginning after December 15, 2016. The adoption of this amendment on November 1, 2016 did not have an impact on our consolidated financial statements and related disclosures.

Table of Contents

In February 2016, the FASB issued Accounting Standards Update 2016-02 (“ASU 2016-02”) which requires lessees to recognize most leases on the balance sheet. This is expected to increase both reported assets and liabilities. The new lease standard does not substantially change lessor accounting. For public companies, the standard will be effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption is permitted. Lessees and lessors will be required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance, using a modified retrospective transition method. The requirements of this standard include a significant increase in required disclosures. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is ongoing.

In March 2016, the FASB issued Accounting Standards Update 2016-09 (“ASU 2016-09”) that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election for forfeitures as they occur. The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those years. Early adoption is permitted. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is ongoing.

In May 2017, the FASB issued Accounting Standards Update 2017-09 (“ASU 2017-09”) that provides guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting. This update is effective for all entities for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is ongoing.

10. INCOME TAXES

We file Federal, New York, California and Pennsylvania state income tax returns. Due to net operating losses, the statute of limitations for Federal and New York State income tax returns remains open to examination by taxing authorities since the fiscal year ended October 31, 1997. We account for interest and penalties related to income tax matters, if any, in marketing, general and administrative expenses. There are no unrecognized income tax benefits as of April 30, 2017 and October 31, 2016.

We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have substantial net operating loss carryforwards for Federal and New York State income tax returns. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets.

Table of Contents

11. COMMITMENT AND CONTINGENCES

Litigation Matters

Other than suits we bring to enforce our patent rights we are not a party to any material pending legal proceedings other than that which arise in the ordinary course of business. We believe that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on our financial position or results of operations.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

GENERAL

In June of 2015, the Company announced the formation of a new subsidiary, Anixa Diagnostics Corporation (“Anixa”), to develop a platform for non-invasive blood tests for the early detection of cancer. That platform is called CchekÔ . In July of 2015, ITUS announced a collaborative research agreement with The Wistar Institute (“Wistar”), the nation’s first independent biomedical research institute and a leading National Cancer Institute designated cancer research center, for the purpose of validating our cancer detection methodologies and establishing protocols for identifying certain biomarkers in the blood which we identified and which are known to be associated with malignancies. In August of 2016 ITUS announced the renewal and expansion of our relationship with Wistar. In October of 2015, ITUS and Wistar announced favorable results from initial testing of a small group of Breast Cancer patients and healthy controls. One hundred percent (100%) of the blood samples tested from patients with varying stages of Breast Cancer showed the presence of the biomarkers we identified, and none of the healthy patient blood samples contained the biomarkers. Breast Cancer is the second most common cancer in the United States and throughout the world.

In April of 2016, ITUS announced that we had demonstrated the efficacy of our CchekÔ early cancer detection platform with Lung Cancer. Lung cancer is the leading cause of death among cancers in the U.S. and throughout the world, accounting for approximately 27 percent of all cancer related deaths in the U.S. and 19 percent worldwide. In September of 2016, ITUS announced that we had demonstrated the efficacy of our CchekÔ early cancer detection platform with Colon Cancer. Colon Cancer is the third most common cancer in men and the second most common cancer in woman worldwide, with approximately 1.4 million new cases diagnosed each year, and approximately 700,000 deaths. At the end of September 2016 through the end of October 2016, the Company made similar announcements with respect to the efficacy of our CchekÔ early cancer detection platform for Melanoma, Ovarian Cancer, Liver Cancer, Thyroid Cancer, and Pancreatic Cancer. On November 15, 2016, ITUS announced that we had demonstrated the efficacy of our CchekÔ early cancer detection platform with six additional cancer types including Appendiceal Cancer (cancer of the appendix), Uterine Cancer, Osteosarcoma (cancer of the bone), Leiomyosarcoma (cancer of the soft tissue), Liposarcoma (cancer of the connective tissue), and Vulvar Cancer (cancer of the vulva).

Table of Contents

On December 7, 2016, ITUS announced preliminary results from itsCchek™ cancer patient efficacy study. Using its most recent protocols and methods for measuring a patient’s immunological response to a malignancy, the Company achieved sensitivity of 92% and specificity of 92% for 88 patient samples, including 54 samples from patients with multiple types and severities of cancer, and 34 healthy patients.

On January 30, 2017, the Company announced that we had demonstrated the efficacy of CchekÔ for Prostate Cancer, bringing the number of cancer types for which the efficacy of CchekÔ has been validated thus far to fifteen.

RESULTS OF OPERATIONS

Six months ended April 30, 2017 compared with six months ended April 30, 2016

Revenue

We had no revenue in the six month periods ended April 30, 2017 and 2016.

Litigation and Licensing Expenses

Litigation and licensing expenses were approximately $2,000 in the six months ended April 30, 2017 compared to approximately $75,000 in the comparable prior year period. Litigation and licensing expenses in the prior period were primarily related to our encrypted audio/video conference calling patents. Litigation and licensing expenses, other than contingent legal fees, are expensed in the period incurred.

Amortization of Patents

Amortization of patents was approximately $163,000 in each of the six month periods ended April 30, 2017 and 2016, respectively. We capitalize patent and patent rights acquisition costs and amortize the cost over the estimated economic useful life.

Research and Development Expenses

Research and development expenses related primarily to the development of our Cchek™ early cancer detection platform and increased by approximately $32,000 to approximately $883,000 in the six months ended April 30, 2017, from approximately $851,000 in the six months ended April 30, 2016. The increase in research and development expenses was primarily due to an increase in patent development costs related to our Cchek™ platform of approximately $100,000 and an increase in costs related to our collaboration with Wistar of approximately $36,000, offset by a decrease in employee compensation and related costs of approximately $88,000 and reduced outside development costs associated with our thin-film display technology of approximately $21,000.

Table of Contents

Marketing, General and Administrative Expenses

Marketing, general and administrative expenses increased by approximately $27,000 to approximately $1,559,000 in the six months ended April 30, 2017, from approximately $1,532,000 in the six months ended April 30, 2016. The increase in marketing, general and administrative expenses was principally due to an increase in employee compensation expense of approximately $41,000 and an increase in corporate insurance costs of approximately $30,000, offset by a decrease in consulting expense of approximately $54,000.

Gain on Extinguishment of Patent Acquisition Obligation

The gain on extinguishment of patent acquisition obligation of approximately $1,548,000 resulted from the difference in the carrying value of the patent acquisition obligation and the fair value of the shares of common stock issued to satisfy the obligation on the date of extinguishment.

Interest Expense

Interest expense increased by approximately $120,000 to approximately $371,000 for the six months ended April 30, 2017 from approximately $251,000 in the six months ended April 30, 2016. The increase in interest expense was principally due to $143,000 of interest related to the secured debenture issued in December 2017, offset by the early extinguishment of the patent acquisition obligation. The remaining interest expense for both periods presented represents the accreted interest on our patent acquisition obligation through the extinguishment date.

Interest Income

Interest income decreased to approximately $2,000 in the six months ended April 30, 2017 compared to approximately $7,000 in the six months ended April 30, 2016 due to a decrease in the amount invested in money market funds and certificates of deposit during the current period.

Deemed Dividend to Preferred Stockholder

The deemed dividend to preferred stockholder of approximately $2,008,000 resulted from the redemption of our Series A Preferred. The difference between the fair value of the consideration given to the holder of our Series A Preferred and the carrying value of the Series A Preferred represented a return to the preferred stockholder and was treated in a similar manner as that of dividends paid on preferred stock.

Three months ended April 30, 2017 compared with three months ended April 30, 2016

Revenue

We had no revenue in the three month periods ended April 30, 2017 and 2016.

Litigation and Licensing Expenses

Litigation and licensing expenses were approximately $200 in the three months ended April 30, 2017 compared to approximately $16,000 in the comparable prior year period. Litigation and licensing expenses, other than contingent legal fees, are expensed in the period incurred.

Table of Contents

Amortization of Patents

Amortization of patents was approximately $81,000 in each of the three month periods ended April 30, 2017 and 2016, respectively. We capitalize patent and patent rights acquisition costs and amortize the cost over the estimated economic useful life.

Research and Development Expenses

Research and development expenses related primarily to the development of ourCchek™ early cancer detection platform and increased by approximately $38,000 to approximately $431,000 in the three months ended April 30, 2017, from approximately $393,000 in the three months ended April 30, 2016. The increase in research and development expenses was primarily due to an increase in patent development costs related to our Cchek™ platform.

Marketing, General and Administrative Expenses

Marketing, general and administrative expenses increased by approximately $40,000 to approximately $699,000 in the three months ended April 30, 2017, from approximately $659,000 in the three months ended April 30, 2016. The increase in marketing, general and administrative expenses was principally due to an increase in legal and auditing fees of approximately $32,000 and an increase in corporate insurance costs of approximately $11,000, offset by a decrease in investor relations expenses of approximately $25,000.

Gain on Extinguishment of Patent Acquisition Obligation

Interest Expense

Interest expense increased by approximately $49,000 to approximately $176,000 for the three months ended April 30, 2017 from approximately $127,000 in the three months ended April 30, 2016. The increase in interest expense was principally due to $89,000 of interest related to the secured debenture issued in December 2017, offset by the early extinguishment of the patent acquisition obligation. The remaining interest expense for both periods presented represents the accreted interest on our patent acquisition obligation through the extinguishment date.

Interest Income

Interest income decreased to approximately $600 in the three months ended April 30, 2017 compared to approximately $3,000 in the three months ended April 30, 2016 due to a decrease in the amount invested in money market funds and certificates of deposit during the current period.

LIQUIDITY AND CAPITAL RESOURCES

Our primary sources of liquidity are cash, cash equivalents and short-term investments.

Table of Contents

During the six months ended April 30, 2017, cash used in operating activities was approximately $1,806,000. Net cash used by investing activities was approximately $1,514,000, which reflects the purchase of certificates of deposit totaling $2,250,000, offset by proceeds from the sale or maturity of certificates of deposit totaling $750,000 and the purchase of property and equipment of approximately $14,000. Cash provided by financing activities was approximately $3,709,000, representing net proceeds from the sale of shares of common stock to Company shareholders through a rights offering receiving proceeds of approximately $4,203,000 and the exercise of stock options, offset by the redemption of our Series A Convertible Preferred Stock (the “Series A Preferred”). As a result, our cash, cash equivalents and short-term investments at April 30, 2017 increased by approximately $1,889,000 to approximately $5,127,000 from approximately $3,238,000 at the end of fiscal year 2016.

Table of Contents

CRITIAL ACCOUNTING POLICIES

The Company’s condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America. In preparing these financial statements, we make assumptions, judgments and estimates that can have a significant impact on amounts reported in our consolidated financial statements. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates and make changes accordingly.

We believe that, of the significant accounting policies discussed in Note 3 to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended October 31, 2016, the following accounting policies require our most difficult, subjective or complex judgments:

· Revenue Recognition; and

· Stock-Based Compensation

Revenue Recognition

Stock-Based Compensation

The compensation cost for stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is recognized as an expense, on a straight-line basis, over the requisite service period (the vesting period of the stock option) which is one to ten years. The Black-Scholes pricing model requires the input of highly subjective assumptions. These variables include, but are not limited to, our stock price volatility over the term of the stock options, and actual and projected employee stock option exercise behaviors. We recorded stock-based compensation expense, related to stock options granted to employees and directors, of approximately $452,000 and $330,000 during the six months ended April 30, 2017 and 2016, respectively.

EFFECT OF RECENTLY ISSUED PRONOUNCEMENTS

We discuss the effect of recently issued pronouncements in the Notes to our Condensed Consolidated Financial Statements.

Table of Contents

FORWARD-LOOKING STATEMENTS

Information included in this Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 and the condensed consolidated financial statements included in this Report. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As of April 30, 2017, we had investments in short-term, fixed rate and highly liquid instruments that have historically been reinvested when they mature throughout the year. Although our existing instruments are not considered at risk with respect to changes in interest rates or markets for these instruments, our rate of return on these securities could be affected at the time of reinvestment, if any.

Item 4. Controls and Procedures.

We carried out an evaluation, under the supervision and with the participation of our management including our President and Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13-15(b) of the Securities Exchange Act of 1934, as amended. Based upon that evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report.

There was no change in our internal control over financial reporting during the second quarter of fiscal year 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

Item 1A. Risk Factors.

There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended October 31, 2016.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the three months ended April 30, 2017, the Company did not issue any unregistered shares.

Item 3. Defaults Upon Senior Securities. None.

Item 4. Mine Safety Disclosures. Not Applicable.

Item 5. Other Information.

(a) On May 16, 2017, the Company closed a registered public offering of 3,425,376 shares of common stock, generating gross proceeds of approximately $3,597,000.

(b) There have been no material changes to the procedures by which security holders may recommend nominees to the Company’s board of directors.

Item 6. Exhibits.

31.1 Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 26, 2017.

31.2 Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 26, 2017.

32.1 Statement of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated May 26, 2017.

32.2 Statement of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated May 26, 2017.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ITUS CORPORATION

	By:	/s/ Robert A. Berman
		Robert A. Berman
		President and Chief Executive Officer
May 26, 2017		(Principal Executive Officer)


	By:	/s/ Michael J. Catelani
		Michael J. Catelani
		Chief Financial Officer
		(Principal Financial and
May 26, 2017		Accounting Officer)

EX-31.1 2 exhibit31_1.htm EXHIBIT 31.1 Exhibit 31.1

Exhibit 31.1

CERTIFICATION

I, Robert A. Berman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of ITUS Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ Robert A. Berman
	Robert A. Berman
	President and Chief Executive Officer
May 26, 2017	(Principal Executive Officer)

EX-31.2 3 exhibit31_2.htm EXHIBIT 31.2 Exhibit 31.2

Exhibit 31.2

CERTIFICATION

I, Michael J. Catelani, certify that:

1. I have reviewed this quarterly report on Form 10-Q of ITUS Corporation;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ Michael J. Catelani
	Michael J. Catelani
	Chief Financial Officer
	(Principal Financial and
May 26, 2017	Accounting Officer)

EX-32.1 4 exhibit32_1.htm EXHIBIT 32.1 Exhibit 32.1

Exhibit 32.1

Statement of Chief Executive Officer

Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Robert A. Berman, the President and Chief Executive Officer of ITUS Corporation, hereby certifies that:

The Company's Form 10-Q Quarterly Report for the period ended April 30, 2017 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Robert A. Berman
	Robert A. Berman
	President and Chief Executive Officer
May 26, 2017	(Principal Executive Officer)

EX-32.2 5 exhibit32_2.htm EXHIBIT 32.2 Exhibit 32.2

Exhibit 32.2

Statement of Chief Financial Officer

Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Michael J. Catelani, the Chief Financial Officer of ITUS Corporation, hereby certifies that:

The Company's Form 10-Q Quarterly Report for the period ended April 30, 2017 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Michael J. Catelani
	Michael J. Catelani
	Chief Financial Officer
	(Principal Financial and
May 26, 2017	Accounting Officer)

EX-101.INS 6 itus-20170430.xml XBRL INSTANCE DOCUMENT 0000715446 2017-04-30 0000715446 2016-10-31 0000715446 us-gaap:PreferredStockMember 2017-04-30 0000715446 us-gaap:PreferredStockMember 2016-10-31 0000715446 us-gaap:SeriesAPreferredStockMember 2017-04-30 0000715446 us-gaap:SeriesAPreferredStockMember 2016-10-31 0000715446 2017-02-01 2017-04-30 0000715446 2016-02-01 2016-04-30 0000715446 2016-11-01 2017-04-30 0000715446 2015-11-01 2016-04-30 0000715446 us-gaap:ResearchAndDevelopmentExpenseMember 2017-02-01 2017-04-30 0000715446 us-gaap:ResearchAndDevelopmentExpenseMember 2016-02-01 2016-04-30 0000715446 us-gaap:ResearchAndDevelopmentExpenseMember 2016-11-01 2017-04-30 0000715446 us-gaap:ResearchAndDevelopmentExpenseMember 2015-11-01 2016-04-30 0000715446 us-gaap:SellingAndMarketingExpenseMember 2017-02-01 2017-04-30 0000715446 us-gaap:SellingAndMarketingExpenseMember 2016-02-01 2016-04-30 0000715446 us-gaap:SellingAndMarketingExpenseMember 2016-11-01 2017-04-30 0000715446 us-gaap:SellingAndMarketingExpenseMember 2015-11-01 2016-04-30 0000715446 us-gaap:PreferredStockMember 2016-10-31 0000715446 us-gaap:CommonStockMember 2016-10-31 0000715446 us-gaap:AdditionalPaidInCapitalMember 2016-10-31 0000715446 us-gaap:RetainedEarningsMember 2016-10-31 0000715446 us-gaap:AdditionalPaidInCapitalMember 2016-11-01 2017-04-30 0000715446 us-gaap:CommonStockMember 2016-11-01 2017-04-30 0000715446 us-gaap:PreferredStockMember 2016-11-01 2017-04-30 0000715446 us-gaap:RetainedEarningsMember 2016-11-01 2017-04-30 0000715446 us-gaap:CommonStockMember 2017-04-30 0000715446 us-gaap:AdditionalPaidInCapitalMember 2017-04-30 0000715446 us-gaap:RetainedEarningsMember 2017-04-30 0000715446 2015-10-31 0000715446 2016-04-30 0000715446 2017-05-25 0000715446 us-gaap:SubsequentEventMember itus:RegisteredPublicOfferingMember 2017-05-16 2017-05-16 0000715446 us-gaap:SubsequentEventMember itus:RegisteredPublicOfferingMember 2017-05-25 0000715446 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2016-11-01 2017-04-30 0000715446 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2016-11-01 2017-04-30 0000715446 us-gaap:EmployeeStockOptionMember 2016-11-01 2017-04-30 0000715446 us-gaap:EmployeeStockOptionMember 2015-11-01 2016-04-30 0000715446 us-gaap:EmployeeStockOptionMember 2017-02-01 2017-04-30 0000715446 us-gaap:EmployeeStockOptionMember 2016-02-01 2016-04-30 0000715446 us-gaap:EmployeeStockOptionMember itus:A2010SharePlanMember 2016-11-01 2017-04-30 0000715446 us-gaap:EmployeeStockOptionMember itus:A2010SharePlanMember 2015-11-01 2016-04-30 0000715446 us-gaap:EmployeeStockOptionMember itus:A2010SharePlanMember 2017-04-30 0000715446 us-gaap:EmployeeStockOptionMember itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember 2016-11-01 2017-04-30 0000715446 us-gaap:EmployeeStockOptionMember itus:ConsultantMember 2016-11-01 2017-04-30 0000715446 us-gaap:EmployeeStockOptionMember itus:ConsultantMember 2015-11-01 2016-04-30 0000715446 itus:A2003SharePlanMember 2016-11-01 2017-04-30 0000715446 itus:A2003SharePlanMember 2016-10-31 0000715446 itus:A2003SharePlanMember 2017-04-30 0000715446 itus:A2003SharePlanMember itus:RangeOfExercisePrices179To775Member 2017-04-30 0000715446 itus:A2003SharePlanMember itus:RangeOfExercisePrices179To775Member 2016-11-01 2017-04-30 0000715446 itus:A2003SharePlanMember itus:RangeOfExercisePrices1350To1750Member 2017-04-30 0000715446 itus:A2003SharePlanMember itus:RangeOfExercisePrices1350To1750Member 2016-11-01 2017-04-30 0000715446 itus:A2003SharePlanMember itus:RangeOfExercisePrices1875To2300Member 2017-04-30 0000715446 itus:A2003SharePlanMember itus:RangeOfExercisePrices1875To2300Member 2016-11-01 2017-04-30 0000715446 itus:A2003SharePlanMember itus:RangeOfExercisePrices2925Member 2017-04-30 0000715446 itus:A2003SharePlanMember itus:RangeOfExercisePrices2925Member 2016-11-01 2017-04-30 0000715446 itus:A2010SharePlanMember 2016-11-01 2017-04-30 0000715446 itus:A2010SharePlanMember 2016-10-31 0000715446 itus:A2010SharePlanMember 2017-04-30 0000715446 itus:A2010SharePlanMember itus:RangeOfExercisePrices258To925Member 2017-04-30 0000715446 itus:A2010SharePlanMember itus:RangeOfExercisePrices258To925Member 2016-11-01 2017-04-30 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember 2016-11-01 2017-04-30 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember 2016-10-31 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember 2017-04-30 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember itus:RangeOfExercisePrices258To556Member 2017-04-30 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember itus:RangeOfExercisePrices258To556Member 2016-11-01 2017-04-30 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2017-04-30 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2017-04-30 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2017-04-30 0000715446 us-gaap:CashEquivalentsMember 2017-04-30 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2017-04-30 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2017-04-30 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2017-04-30 0000715446 us-gaap:CertificatesOfDepositMember 2017-04-30 0000715446 us-gaap:FairValueInputsLevel1Member 2017-04-30 0000715446 us-gaap:FairValueInputsLevel2Member 2017-04-30 0000715446 us-gaap:FairValueInputsLevel3Member 2017-04-30 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2016-10-31 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2016-10-31 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2016-10-31 0000715446 us-gaap:CashEquivalentsMember 2016-10-31 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2016-10-31 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2016-10-31 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2016-10-31 0000715446 us-gaap:CertificatesOfDepositMember 2016-10-31 0000715446 us-gaap:FairValueInputsLevel1Member 2016-10-31 0000715446 us-gaap:FairValueInputsLevel2Member 2016-10-31 0000715446 us-gaap:FairValueInputsLevel3Member 2016-10-31 0000715446 itus:PatentAcquisitionObligationMember us-gaap:FairValueInputsLevel1Member 2017-04-30 0000715446 itus:PatentAcquisitionObligationMember us-gaap:FairValueInputsLevel2Member 2017-04-30 0000715446 itus:PatentAcquisitionObligationMember us-gaap:FairValueInputsLevel3Member 2017-04-30 0000715446 itus:PatentAcquisitionObligationMember 2017-04-30 0000715446 itus:PatentAcquisitionObligationMember us-gaap:FairValueInputsLevel1Member 2016-10-31 0000715446 itus:PatentAcquisitionObligationMember us-gaap:FairValueInputsLevel2Member 2016-10-31 0000715446 itus:PatentAcquisitionObligationMember us-gaap:FairValueInputsLevel3Member 2016-10-31 0000715446 itus:PatentAcquisitionObligationMember 2016-10-31 0000715446 us-gaap:CommonStockMember itus:MeetrixMember 2017-03-27 2017-03-27 0000715446 itus:MeetrixMember 2017-03-27 0000715446 itus:MeetrixMember 2017-03-27 2017-03-27 0000715446 2016-11-11 0000715446 2016-12-06 2016-12-06 0000715446 2016-12-09 2016-12-09 0000715446 us-gaap:SecuredDebtMember 2016-12-09 0000715446 itus:RedemptionDebentureMember 2016-12-09 0000715446 itus:DueOnOrBeforeJune12017Member 2016-12-09 0000715446 2016-12-09 0000715446 itus:RedemptionWarrantMember 2017-04-30 0000715446 us-gaap:EmployeeStockOptionMember 2016-11-01 2017-04-30 0000715446 us-gaap:WarrantMember 2016-11-01 2017-04-30 0000715446 us-gaap:EmployeeStockOptionMember 2015-11-01 2016-04-30 0000715446 us-gaap:EmployeeStockOptionMember 2016-02-01 2016-04-30 0000715446 us-gaap:WarrantMember 2015-11-01 2016-04-30 0000715446 us-gaap:WarrantMember 2016-02-01 2016-04-30 0000715446 us-gaap:SeriesAPreferredStockMember 2015-11-01 2016-04-30 0000715446 us-gaap:SeriesAPreferredStockMember 2016-02-01 2016-04-30 0000715446 us-gaap:EmployeeStockOptionMember 2017-02-01 2017-04-30 0000715446 us-gaap:WarrantMember 2017-02-01 2017-04-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure

2876897

2488323

2250000

750000

64647

162069

5191544

3400392

1908423 2071071

149487

156644

7249454

5628107

660023

468756

3000000

3660023

468756

4171876

3660023

4640632

14000

116949

87524

156066446

152051144

-152593964

-151165193

3589431

987475

7249454

5628107

1127688

965040

68228

46950

100

19860

100

140

0.01

24000000

11694863

8752387

11694863

8752387

225 15521 2346 75162

81324

162648

431124

392589

882754

850910

699345

658953

1559230

1532106

1212018

1148387

2606978

2620826

-1212018

-1148387

-2606978

-2620826

1547608

175727

126980

371026

250881

626

3473

1625

6724

160489

-1271894

-1428771

-2864983

160489

-1271894

-1428771

-2864983

2008775

160489

-1271894

-3437546

-2864983

0.02

-0.15

0.02

-0.15

-0.37

-0.33

9734171

8736024

9736571

8736024

9236351

8731489

68928

72496

148628

91442

122991

144758

303028

238307

140

14000

8752387

87524

152051144

-151165193

451655

2200

5643

5665

3463

17776

17811

-140

-14000

-3486000

-3500000

947606 9476 2842818 2852294

1989207

19892

4183410

4203302

-1428771

11694863

116949

156066446

-152593964

451655

329749

17811

11361

21278

13881

-228026 -250881

30000

11800

-97422

-87496

161267

132031

-18883

-1806272

-1884019

2250000

1550000

750000

1800000

14121

141110

-1514121

108890

500000

4203302

5665

18231

3708967

18231

388574

-1756898

4369219

2612321

3000000

4399902

ITUS CORPORATION 10-Q --10-31 15120239 false 0000715446 Yes No Smaller Reporting Company No 2017 Q2 2017-04-30

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> 1.         BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “ITUS” means ITUS Corporation and its wholly-owned subsidiaries.  From inception through October 2012, our primary operations involved the development of patented technologies in the areas of thin-film displays and encryption.  Beginning in October of 2012 under the leadership of a new management team, we recapitalized the Company, changed the Company’s name and ticker symbol, relocated the Company’s headquarters, and modernized its systems.  In July of 2015, the Company’s stock was accepted for listing and began trading on the NASDAQ Capital Market. In June of 2015, the Company announced the formation of a new subsidiary, Anixa Diagnostics Corporation (“Anixa”), to develop a platform for non-invasive blood tests for the early detection of cancer.  That platform is called CchekÔ.  In July of 2015, ITUS announced a collaborative research agreement with The Wistar Institute (“Wistar”), the nation’s first independent biomedical research institute and a leading National Cancer Institute designated cancer research center, for the purpose of validating our cancer detection methodologies and establishing protocols for identifying certain biomarkers in the blood which we identified and which are known to be associated with malignancies.  In August of 2016 ITUS announced the renewal and expansion of our relationship with Wistar.  From October of 2015 through January of 2017, ITUS announced that we had demonstrated the efficacy of our CchekÔ early cancer detection platform with Breast Cancer, Lung Cancer Melanoma, Ovarian Cancer, Liver Cancer, Thyroid Cancer, Pancreatic Cancer, Appendiceal Cancer (cancer of the appendix), Uterine Cancer, Osteosarcoma (cancer of the bone), Leiomyosarcoma (cancer of the soft tissue), Liposarcoma (cancer of the connective tissue), Vulvar Cancer (cancer of the vulva), and Prostate Cancer, bringing the number of cancer types for which the efficacy of CchekÔhas been validated thus far to fifteen. Over the next several quarters, we expect Cchek™ to be the primary focus of the Company.  As part of our legacy operations, the Company remains engaged in limited patent licensing activities in the area of encrypted audio/video conference calling.  We do not expect these activities to be a significant part of the Company’s ongoing operations. In the past, our revenue has been derived from technology licensing and the sale of patented technologies, including in connection with the settlement of litigation.  In addition to Anixa, the Company may make investments in and form new companies to develop additional emerging technologies. Funding and Management’s Plans During the six months ended April 30, 2017, cash used in operating activities was approximately $1,806,000.  Net cash used by investing activities was approximately $1,514,000, which reflects the purchase of certificates of deposit totaling $2,250,000, offset by proceeds from the sale or maturity of certificates of deposit totaling $750,000 and the purchase of property and equipment of approximately $14,000.  Cash provided by financing activities was approximately $3,709,000, representing net proceeds from the sale of shares of common stock to Company shareholders through a rights offering receiving proceeds of approximately $4,203,000 and the exercise of stock options, offset by the redemption of our Series A Convertible Preferred Stock (the “Series A Preferred”) of $500,000.  As a result, our cash, cash equivalents and short-term investments at April 30, 2017 increased by approximately $1,889,000 to approximately $5,127,000 from approximately $3,238,000 at the end of fiscal year 2016. Based on currently available information as of May 25, 2017, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows from operations will be sufficient to fund our activities and debt obligations for the next 12 months.  However, our projections of future cash needs and cash flows may differ from actual results.  To date, we have relied primarily upon cash from the public and private sale of equity and debt securities to generate the working capital needed to finance our operations.  If current cash on hand, cash equivalents, short term investments and cash that may be generated from our business operations are insufficient to continue to operate our business and repay our indebtedness, we will be required to obtain more working capital.  We may seek to obtain working capital through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible and as permitted pursuant to our existing indebtedness.  We cannot be certain that additional funding will be available on acceptable terms, or at all.  If we do identify sources for additional funding, the sale of additional equity securities or convertible debt could result in dilution to our stockholders.  Additionally, the sale of equity securities or issuance of debt securities may be subject to certain security holder approvals or may result in the downward adjustment of the exercise or conversion price of our outstanding securities.  We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all.  If we fail to obtain additional working capital as and when needed, it could have a material adverse impact on our business, results of operations and financial condition.  Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations. Subsequent Event On May 16, 2017, the Company completed a registered public offering of 3,425,376 shares of common stock, generating net proceeds of approximately $3,214,000.  The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the potential payment of corporate debt. As of May 25, 2017, significant balance sheet amounts affected by this offering are approximately as follows: <table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 79%; background: #cceeff; white-space: nowrap; padding: 0in;"> Cash, cash equivalents and short term investments </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; height: 15.75pt; width: 1%; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in; border-color: currentcolor currentcolor windowtext;"> $ </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; height: 15.75pt; width: 22%; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in; border-color: currentcolor currentcolor windowtext;"> 8,104,000 </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 79%; white-space: nowrap; padding: 0in;"> Total assets </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; border-color: currentcolor currentcolor windowtext; height: 15.75pt; width: 1%; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;"> $ </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; border-color: currentcolor currentcolor windowtext; height: 15.75pt; width: 22%; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;"> 10,227,000 </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 79%; background: #cceeff; white-space: nowrap; padding: 0in;"> Total shareholders’ equity </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; border-color: currentcolor currentcolor windowtext; height: 15.75pt; width: 1%; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;"> $ </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; border-color: currentcolor currentcolor windowtext; height: 15.75pt; width: 22%; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;"> 6,567,000 </td> </tr> </table> Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X.  Accordingly, certain information and footnotes required by generally accepted accounting principles in annual financial statements have been omitted or condensed.  These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended October 31, 2016, as reported by us in our Annual Report on Form 10-K.  The October 31, 2016 consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (“US GAAP”).  The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of April 30, 2017, and results of operations and cash flows for the interim periods represented.  The results of operations for the six and three months ended April 30, 2017 are not necessarily indicative of the results to be expected for the entire year. Revenue Recognition Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed pursuant to the terms of the arrangement, (iii) amounts are fixed or determinable, and (iv) the collectability of amounts is reasonably assured. Patent Licensing In certain instances, our past revenue arrangements have provided for the payment of contractually determined fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company.  These arrangements typically include some combination of the following:  (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation.  In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents.  Pursuant to the terms of these agreements, we had no further obligations.   As such, the earnings process was complete and revenue has been recognized upon the execution of the agreement, when collectability was reasonably assured, and when all other revenue recognition criteria were met. Intangible Assets Our only identifiable intangible assets are patents and patent rights.  We capitalize patent and patent rights acquisition costs and amortize the cost over the estimated economic useful life.  We did not capitalize any patent acquisition costs during the six months ended April 30, 2017 and 2016. We recorded patent amortization expense of approximately $163,000 during each of the six month periods ended April 30, 2017 and 2016, respectively<a name="_DV_M82"></a>, and approximately $81,000 during each of the three month periods ended April 30, 2017 and 2016, respectively. </div>

1889000

5127000

3238000

3425376

3214000

<table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 79%; background: #cceeff; white-space: nowrap; padding: 0in;"> Cash, cash equivalents and short term investments </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; height: 15.75pt; width: 1%; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in; border-color: currentcolor currentcolor windowtext;"> $ </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; height: 15.75pt; width: 22%; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in; border-color: currentcolor currentcolor windowtext;"> 8,104,000 </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 79%; white-space: nowrap; padding: 0in;"> Total assets </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; border-color: currentcolor currentcolor windowtext; height: 15.75pt; width: 1%; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;"> $ </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; border-color: currentcolor currentcolor windowtext; height: 15.75pt; width: 22%; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;"> 10,227,000 </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 79%; background: #cceeff; white-space: nowrap; padding: 0in;"> Total shareholders’ equity </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; border-color: currentcolor currentcolor windowtext; height: 15.75pt; width: 1%; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;"> $ </td> <td style="border-width: 0px 0px 2.25pt; border-style: none none double; border-color: currentcolor currentcolor windowtext; height: 15.75pt; width: 22%; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;"> 6,567,000 </td> </tr> </table>

8104000

10227000

6567000

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> 2.         STOCK BASED COMPENSATION The Company maintains stock equity incentive plans under which the Company grants non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants. Stock Option Compensation Expense The compensation cost for stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is recognized as an expense, on a straight-line basis, over the requisite service period (the vesting period of the stock option) which is one to ten years. We recorded stock-based compensation expense, related to stock options granted to employees and directors, of approximately $452,000 and $330,000 during the six months ended April 30, 2017 and 2016, respectively, and approximately $192,000 and $217,000 during the three months ended April 30, 2017 and 2016, respectively. Stock Option Activity During the six months ended April 30, 2017 and 2016, we granted options to purchase 106,000 shares and 545,000 shares of common stock, respectively, to employees and directors at exercise prices of $5.00 and $2.92 per share, respectively, pursuant to the ITUS Corporation 2010 Share Incentive Plan (the "2010 Share Plan”).  During the six months ended April 30, 2017 and 2016, stock options to purchase 2,200 and 7,080 shares of common stock, respectively, were exercised with aggregate proceeds of approximately $6,000 and $18,000, respectively.   Stock Option Plans As of April 30, 2017, we have two stock option plans:  the ITUS Corporation 2003 Share Incentive Plan (the "2003 Share Plan") and the 2010 Share Plan, which were adopted by our Board of Directors on April 21, 2003 and July 14, 2010, respectively.  The 2003 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to key employees, directors and consultants.  In accordance with the provisions of the 2003 Share Plan, the plan terminated with respect to the ability to grant future options on April 21, 2013.  Information regarding the 2003 Share Plan for the six months ended April 30, 2017 is as follows: <table width="733" style="WIDTH:550pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:315.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:63.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:84pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="3" valign="bottom">  Weighted Average Exercise Price Per Share</td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:69.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="3" valign="bottom"> Aggregate Intrinsic Value</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:315.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:63.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:315.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:63.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Shares</td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:315.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Outstanding at October 31, 2016</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60.85pt; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> 225,600</td> <td style="HEIGHT:15pt; WIDTH:8.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:78pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 18.69</td> <td style="HEIGHT:15pt; WIDTH:8.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:63.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:315.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Exercised</td> <td style="HEIGHT:15.75pt; WIDTH:60.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> (2,200)</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:78pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2.58</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:63.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:315.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Forfeited</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.85pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> (34,400)</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:78pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 17.85</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:63.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:315.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Outstanding and exercisable at      April 30, 2017</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.85pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> 189,000</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:78pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 19.03</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:63.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 390</td></tr></table> The following table summarizes information about stock options outstanding and exercisable under the 2003 Share Plan as of April 30, 2017: <table style="width: 550pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 121.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Number Outstanding and Exercisable </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 121.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Weighted Average Remaining Contractual Life (in years) </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 98.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 98.25pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="3" valign="bottom"> Weighted Average Exercise Price </td> </tr> <tr style="height: 15pt;"> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="2" valign="bottom"> Range of Exercise Prices </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; background: #cceeff; padding: 0in;">    $1.79 - $7.75 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;"> 39,000 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;"> 1.32 </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 98.25pt; background: #cceeff; padding: 0in;"> 2.92 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; padding: 0in;">    $13.50 - $17.50 </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; padding: 0in;"> 21,400 </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; padding: 0in;"> .45 </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 98.25pt; padding: 0in;"> 16.46 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; background: #cceeff; padding: 0in;">    $18.75 - $23.00 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;"> 88,600 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;"> .37 </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 98.25pt; background: #cceeff; padding: 0in;"> 22.13 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; padding: 0in;"> $29.25 </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; padding: 0in;"> 40,000 </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; padding: 0in;"> .31 </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 98.25pt; padding: 0in;"> 29.25 </td> </tr> </table> The 2010 Share Plan provides for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to key employees, directors and consultants.  As of April 30, 2017, the 2010 Share Plan had 764,000 shares available for future grants.  Information regarding the 2010 Share Plan for the six months ended April 30, 2017 is as follows: <table style="width: 550pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 312.75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 65.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 81pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" rowspan="3" valign="bottom">  Weighted Average Exercise Price Per Share </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 72.75pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" rowspan="3" valign="bottom"> Aggregate Intrinsic Value </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 312.75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 65.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 312.75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 65.25pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> Shares </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 312.75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> Options Outstanding at October 31, 2016 </td> <td style="height: 15pt; width: 65.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 1,080,872 </td> <td style="height: 15pt; width: 9pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 6pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> 3.12 </td> <td style="height: 15pt; width: 9pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 6pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 66.75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 312.75pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">     Granted </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 65.25pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> 106,000 </td> <td style="height: 15.75pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15.75pt; width: 6pt; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15.75pt; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom"> 5.00 </td> <td style="height: 15.75pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15.75pt; width: 6pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15.75pt; width: 66.75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 312.75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> Options Outstanding  at April 30, 2017 </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 65.25pt; background: #cceeff; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> 1,186,872 </td> <td style="height: 15.75pt; width: 9pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15.75pt; width: 6pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15.75pt; width: 75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> 3.29 </td> <td style="height: 15.75pt; width: 9pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15.75pt; width: 6pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15.75pt; width: 66.75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> - </td> </tr> <tr style="height: 16.5pt;"> <td style="height: 16.5pt; width: 312.75pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> Options Exercisable at April 30, 2017 </td> <td style="border-top: 0px; height: 16.5pt; border-right: 0px; width: 65.25pt; background-image: none; background-repeat: repeat; background-attachment: scroll; border-bottom: windowtext 2.25pt double; background-position: 0% 0%; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> 793,994 </td> <td style="height: 16.5pt; width: 9pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 16.5pt; width: 6pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 16.5pt; width: 75pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 3.15 </td> <td style="height: 16.5pt; width: 9pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 16.5pt; width: 6pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 16.5pt; width: 66.75pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> - </td> </tr> </table> The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2017: <table style="width: 550.1pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 11px; width: 226.5pt; white-space: nowrap; padding: 0in;" colspan="4" valign="bottom"> Options Outstanding </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 11px; width: 225pt; white-space: nowrap; padding: 0in;" colspan="4" valign="bottom"> Options Exercisable </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 55px; width: 1in; white-space: nowrap; padding: 0in;" rowspan="5" valign="bottom"> Weighted Average Remaining Contractual  Life (in years) </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 55px; width: 71.25pt; white-space: nowrap; padding: 0in;" rowspan="5" valign="bottom"> Weighted Average Remaining Contractual  Life  (in years) </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 44px; width: 71.25pt; white-space: nowrap; padding: 0in;" rowspan="4" valign="bottom"> Weighted Average Exercise  Price </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 33px; width: 71.25pt; white-space: nowrap; padding: 0in;" rowspan="3" valign="bottom"> Weighted Average Exercise Price </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 11px;"> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 22px; width: 75pt; white-space: nowrap; padding: 0in;" rowspan="2" valign="bottom"> Range of Exercise Prices </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 22px; width: 1in; white-space: nowrap; padding: 0in;" rowspan="2" valign="bottom"> Number Outstanding </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 22px; width: 71.25pt; white-space: nowrap; padding: 0in;" rowspan="2" valign="bottom"> Number Exercisable </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> $2.58 - $9.25 </td> <td style="height: 11px; width: 12pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 1,186,872 </td> <td style="height: 11px; width: 1in; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 7.42 </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 3.29 </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 793,994 </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 6.65 </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 3.15 </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in; text-align: right;" valign="bottom">  . </td> </tr> </table> In addition to options granted under the 2003 Share Plan and the 2010 Share Plan, the Board of Directors approved the grant of stock options to purchase 1,780,000 shares.  Information regarding stock options outstanding that were not granted under the 2003 Plan or the 2010 Plan for the six months ended April 30, 2017 is as follows: <table width="733" style="WIDTH:550.1pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:313.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:75.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="3" valign="bottom">  Weighted Average  Exercise Price Per Share</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:73.5pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="3" valign="bottom"> Aggregate Intrinsic Value</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:313.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:66pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:313.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Shares</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:313.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Outstanding at October 31, 2016</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:66pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 1,780,000</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:69.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2.70</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:67.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:16.5pt"> <td style="HEIGHT:16.5pt; WIDTH:313.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Outstanding  and exercisable at      April 30, 2017</td> <td style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 1,780,000</td> <td style="HEIGHT:16.5pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:16.5pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:16.5pt; WIDTH:69.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2.70</td> <td style="HEIGHT:16.5pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:16.5pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:16.5pt; WIDTH:67.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td></tr></table> The following table summarizes information about stock options outstanding and exercisable that were not granted under the 2003 Share Plan or the 2010 Share Plan as of April 30, 2017: <table style="width: 550pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 121.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Number Outstanding and Exercisable </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 121.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Weighted Average Remaining Contractual Life (in years) </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 98.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 98.25pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="3" valign="bottom"> Weighted Average Exercise  Price </td> </tr> <tr style="height: 15pt;"> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="2" valign="bottom"> Range of Exercise Prices </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; background: #cceeff; padding: 0in;" valign="bottom"> $2.58 - $5.56 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;" valign="bottom"> 1,780,000 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;" valign="bottom"> 5.26 </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 98.25pt; background: #cceeff; padding: 0in;" valign="bottom"> 2.70 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 98.25pt; background: #cceeff; padding: 0in;" valign="bottom">  . </td> </tr> </table> Stock Awards <a name="_DV_M176"></a> We account for stock awards granted to employees and consultants based on the grant date market price of the underlying common stock.  During the six months ended April 30, 2017 and 2016, we issued 3,463 shares and 3,701 shares, respectively, of common stock to consultants for services rendered.  We recorded consulting expense for the six months ended April 30, 2017 and 2016 of approximately $18,000 and $11,000, respectively, for the shares of common stock issued to consultants.  </div>

P1Y

P10Y

452000

330000

192000

217000

106000

545000

5.00

2.92

2200

7080

6000

18000

764000

1780000

3463

3701

18000 11000

<table width="733" style="WIDTH:550pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:315.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:63.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:84pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="3" valign="bottom">  Weighted Average Exercise Price Per Share</td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:69.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="3" valign="bottom"> Aggregate Intrinsic Value</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:315.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:63.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:315.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:63.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Shares</td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:315.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Outstanding at October 31, 2016</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60.85pt; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> 225,600</td> <td style="HEIGHT:15pt; WIDTH:8.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:78pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 18.69</td> <td style="HEIGHT:15pt; WIDTH:8.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:63.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:315.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Exercised</td> <td style="HEIGHT:15.75pt; WIDTH:60.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> (2,200)</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:78pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2.58</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:63.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:315.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Forfeited</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.85pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> (34,400)</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:78pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 17.85</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:63.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:315.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Outstanding and exercisable at      April 30, 2017</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.85pt; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> 189,000</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:78pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 19.03</td> <td style="HEIGHT:15.75pt; WIDTH:8.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:63.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 390</td></tr></table>

225600

18.69

2200

2.58

34400

17.85

189000 19.03 390

<table style="width: 550pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 121.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Number Outstanding and Exercisable </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 121.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Weighted Average Remaining Contractual Life (in years) </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 98.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 98.25pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="3" valign="bottom"> Weighted Average Exercise Price </td> </tr> <tr style="height: 15pt;"> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="2" valign="bottom"> Range of Exercise Prices </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; background: #cceeff; padding: 0in;">    $1.79 - $7.75 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;"> 39,000 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;"> 1.32 </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 98.25pt; background: #cceeff; padding: 0in;"> 2.92 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; padding: 0in;">    $13.50 - $17.50 </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; padding: 0in;"> 21,400 </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; padding: 0in;"> .45 </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 98.25pt; padding: 0in;"> 16.46 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; background: #cceeff; padding: 0in;">    $18.75 - $23.00 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;"> 88,600 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;"> .37 </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 98.25pt; background: #cceeff; padding: 0in;"> 22.13 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; padding: 0in;"> $29.25 </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; padding: 0in;"> 40,000 </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; padding: 0in;"> .31 </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 98.25pt; padding: 0in;"> 29.25 </td> </tr> </table>

39000 P1Y116D 2.92 21400 P164D 16.46 88600 P135D 22.13 40000 P113D 29.25

<table style="width: 550pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 312.75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 65.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 81pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" rowspan="3" valign="bottom">  Weighted Average Exercise Price Per Share </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 72.75pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" rowspan="3" valign="bottom"> Aggregate Intrinsic Value </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 312.75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 65.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 312.75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 65.25pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> Shares </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 312.75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> Options Outstanding at October 31, 2016 </td> <td style="height: 15pt; width: 65.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 1,080,872 </td> <td style="height: 15pt; width: 9pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 6pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> 3.12 </td> <td style="height: 15pt; width: 9pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 6pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 66.75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 312.75pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">     Granted </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 65.25pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> 106,000 </td> <td style="height: 15.75pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15.75pt; width: 6pt; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15.75pt; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom"> 5.00 </td> <td style="height: 15.75pt; width: 9pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15.75pt; width: 6pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15.75pt; width: 66.75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 312.75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> Options Outstanding  at April 30, 2017 </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 65.25pt; background: #cceeff; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> 1,186,872 </td> <td style="height: 15.75pt; width: 9pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15.75pt; width: 6pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15.75pt; width: 75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> 3.29 </td> <td style="height: 15.75pt; width: 9pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15.75pt; width: 6pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15.75pt; width: 66.75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> - </td> </tr> <tr style="height: 16.5pt;"> <td style="height: 16.5pt; width: 312.75pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> Options Exercisable at April 30, 2017 </td> <td style="border-top: 0px; height: 16.5pt; border-right: 0px; width: 65.25pt; background-image: none; background-repeat: repeat; background-attachment: scroll; border-bottom: windowtext 2.25pt double; background-position: 0% 0%; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> 793,994 </td> <td style="height: 16.5pt; width: 9pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 16.5pt; width: 6pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 16.5pt; width: 75pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 3.15 </td> <td style="height: 16.5pt; width: 9pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 16.5pt; width: 6pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 16.5pt; width: 66.75pt; background-image: none; background-repeat: repeat; background-attachment: scroll; background-position: 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> - </td> </tr> </table>

1080872

3.12

106000

5.00

1186872

3.29

793994

3.15

<table style="width: 550.1pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 11px; width: 226.5pt; white-space: nowrap; padding: 0in;" colspan="4" valign="bottom"> Options Outstanding </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 11px; width: 225pt; white-space: nowrap; padding: 0in;" colspan="4" valign="bottom"> Options Exercisable </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 55px; width: 1in; white-space: nowrap; padding: 0in;" rowspan="5" valign="bottom"> Weighted Average Remaining Contractual  Life (in years) </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 55px; width: 71.25pt; white-space: nowrap; padding: 0in;" rowspan="5" valign="bottom"> Weighted Average Remaining Contractual  Life  (in years) </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 44px; width: 71.25pt; white-space: nowrap; padding: 0in;" rowspan="4" valign="bottom"> Weighted Average Exercise  Price </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 33px; width: 71.25pt; white-space: nowrap; padding: 0in;" rowspan="3" valign="bottom"> Weighted Average Exercise Price </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 11px;"> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 22px; width: 75pt; white-space: nowrap; padding: 0in;" rowspan="2" valign="bottom"> Range of Exercise Prices </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 22px; width: 1in; white-space: nowrap; padding: 0in;" rowspan="2" valign="bottom"> Number Outstanding </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 22px; width: 71.25pt; white-space: nowrap; padding: 0in;" rowspan="2" valign="bottom"> Number Exercisable </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-width: 0px 0px 1pt; border-style: none none solid; border-color: currentcolor currentcolor windowtext; height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> $2.58 - $9.25 </td> <td style="height: 11px; width: 12pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 1,186,872 </td> <td style="height: 11px; width: 1in; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 7.42 </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 3.29 </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 793,994 </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 6.65 </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom"> 3.15 </td> </tr> <tr style="height: 11px;"> <td style="height: 11px; width: 75pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 12pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 1in; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 11.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 11px; width: 71.25pt; background: #cceeff none repeat scroll 0% 0%; white-space: nowrap; padding: 0in; text-align: right;" valign="bottom">  . </td> </tr> </table>

1186872

P7Y153D

3.29

793994

P6Y237D

3.15

1780000

2.70

1780000 2.70

<table style="width: 550pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 121.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Number Outstanding and Exercisable </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 121.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Weighted Average Remaining Contractual Life (in years) </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 98.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 98.25pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="3" valign="bottom"> Weighted Average Exercise  Price </td> </tr> <tr style="height: 15pt;"> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 165pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="2" valign="bottom"> Range of Exercise Prices </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; background: #cceeff; padding: 0in;" valign="bottom"> $2.58 - $5.56 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;" valign="bottom"> 1,780,000 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;" valign="bottom"> 5.26 </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 98.25pt; background: #cceeff; padding: 0in;" valign="bottom"> 2.70 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 165pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 121.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 98.25pt; background: #cceeff; padding: 0in;" valign="bottom">  . </td> </tr> </table>

1780000 P5Y94D 2.70

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> 3.         FAIR VALUE MEASUREMENTS US GAAP defines fair value and establishes a framework for measuring fair value.  We have categorized our financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below.  If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 - Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 - Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.   Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset and liabilities. The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of April 30, 2017: <table width="733" style="WIDTH:550.1pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:246.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:69pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 1</td> <td style="HEIGHT:15pt; WIDTH:11.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:68.25pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 2</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 3</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Total</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:246.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:62.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:11.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:61.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:246.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Money market funds –       Cash equivalents</td> <td style="HEIGHT:15pt; WIDTH:6.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:62.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,585,760</td> <td style="HEIGHT:15pt; WIDTH:11.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:61.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> 2,585,760</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:246.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Certificates of deposit –      Short-term investments</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:62.25pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:11.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:61.5pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,250,000</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,250,000</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:236.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Total financial assets</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:62.25pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,585,760</td> <td style="HEIGHT:15.75pt; WIDTH:11.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:61.5pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,250,000</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 4,835,760</td></tr></table> <a name="FIS_UNIDENTIFIED_TABLE_18"></a>The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2016:<a name="FIS_UNIDENTIFIED_TABLE_19"></a> <table width="733" style="WIDTH:550.1pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:252.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 1</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 2</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 3</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Total</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:252.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:252.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Money market funds –      Cash equivalents</td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 1,899,136</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> 1,899,136</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:252.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Certificates of deposit –     Short-term investments</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 750,000</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 750,000</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:242.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Total financial assets</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 1,899,136</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 750,000</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,649,136</td></tr></table> The following table presents the hierarchy for our financial liabilities measured at fair value on the transaction date and then adjusted for the subsequent accretion of interest as of April 30, 2017: <table width="733" style="WIDTH:550.1pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:253.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">   </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 1</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 2</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 3</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Total</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:253.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:253.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Patent acquisition obligation</td> <td style="HEIGHT:15pt; WIDTH:6.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> -</td></tr></table> The following table presents the hierarchy for our financial liabilities measured at fair value on the transaction date and then adjusted for the subsequent accretion of interest as of October 31, 2016: <table width="733" style="WIDTH:550.1pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:253.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">   </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 1</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 2</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 3</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Total</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:253.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:253.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Patent acquisition obligation</td> <td style="HEIGHT:15pt; WIDTH:6.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 4,171,876 </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> 4,171,876</td></tr></table> <a name="eolPage31"></a><a name="FORM10Q_HTM_PAGE_41"></a>The following table sets forth the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: <table width="733" style="WIDTH:550.1pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:473.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:11.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:65.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:473.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;"> Patent acquisition obligation</td> <td style="HEIGHT:15pt; WIDTH:11.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:65.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:473.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;"> Balance October 31, 2016</td> <td style="HEIGHT:15pt; WIDTH:11.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:65.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;"> 4,171,876</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:473.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;"> Accreted interest on patent obligation</td> <td style="HEIGHT:15pt; WIDTH:11.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:65.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;"> 228,026</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:473.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;"> Extinguishment of patent obligation</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.25pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:65.25pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;"> (4,399,902)</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:473.25pt; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;"> Balance April 30, 2017</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.25pt; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:windowtext 2.25pt double; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:65.25pt; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:windowtext 2.25pt double; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;"> -</td></tr></table> Our non-financial assets that are measured on a non-recurring basis include our patents and property and equipment which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists.  The estimated fair value of prepaid expenses, accounts payable and accrued expenses approximates their individual carrying amounts due to the short term nature of these measurements.  Cash and cash equivalents are stated at carrying value which approximates fair value.  </div>

<table width="733" style="WIDTH:550.1pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:246.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:69pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 1</td> <td style="HEIGHT:15pt; WIDTH:11.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:68.25pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 2</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 3</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Total</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:246.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:62.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:11.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:61.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:246.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Money market funds –       Cash equivalents</td> <td style="HEIGHT:15pt; WIDTH:6.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:62.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,585,760</td> <td style="HEIGHT:15pt; WIDTH:11.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:61.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> 2,585,760</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:246.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Certificates of deposit –      Short-term investments</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:62.25pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:11.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:61.5pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,250,000</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,250,000</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:236.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Total financial assets</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:62.25pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,585,760</td> <td style="HEIGHT:15.75pt; WIDTH:11.25pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:61.5pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,250,000</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 4,835,760</td></tr></table><table width="733" style="WIDTH:550.1pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:252.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 1</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 2</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Level 3</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:66.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Total</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:252.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:60.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:252.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Money market funds –      Cash equivalents</td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 1,899,136</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:6pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:60.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> 1,899,136</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:252.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Certificates of deposit –     Short-term investments</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 750,000</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:10.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:6pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 750,000</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:242.75pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Total financial assets</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 1,899,136</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 750,000</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15.75pt; WIDTH:10.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:6pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:60.75pt; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2,649,136</td></tr></table>

2585760

2250000

2585760

2250000

4835760

1899136

750000

1899136

750000

2649136

4171876

228026 -4399902

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> <a name="eolPage32"></a>4.         INVESTMENTS At April 30, 2017 and October 31, 2016, we had certificates of deposit of $2,250,000 and $750,000, respectively, which were classified as short-term investments and reported at fair value.  </div>

2250000

750000

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> 5.         ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expense consist of the following as of: <table style="width: 550pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 385.5pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 77.25pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" rowspan="2" valign="bottom"> April 30, 2017 </td> <td style="height: 15pt; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 75.75pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" colspan="2" rowspan="2" valign="bottom"> October 31, 2016 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 385.5pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 11.25pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 385.5pt; background: #cceeff; padding: 0in;"> Accounts payable </td> <td style="height: 15pt; width: 21.75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 55.5pt; background: #cceeff; padding: 0in;"> 448,353 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 65.25pt; background: #cceeff; padding: 0in;"> 373,224 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 385.5pt; padding: 0in;"> Payroll and related expenses </td> <td style="height: 15pt; width: 21.75pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 55.5pt; padding: 0in;"> 59,497 </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 65.25pt; padding: 0in;"> 49,901 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 385.5pt; background: #cceeff; padding: 0in;"> Accrued interest on secured debenture </td> <td style="height: 15pt; width: 21.75pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 55.5pt; background: #cceeff; padding: 0in;"> 30,000 </td> <td style="height: 15pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 10.5pt; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 65.25pt; background: #cceeff; padding: 0in;"> - </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 385.5pt; padding: 0in;"> Accrued other </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 21.75pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 55.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;"> 122,173 </td> <td style="height: 15pt; width: 11.25pt; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10.5pt; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 65.25pt; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;"> 45,631 </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 385.5pt; background: #cceeff; padding: 0in;" valign="bottom"> Total </td> <td style="border-top: 0px; height: 15.75pt; background: #cceeff; border-right: 0px; width: 21.75pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="border-top: 0px; height: 15.75pt; background: #cceeff; border-right: 0px; width: 55.5pt; border-bottom: windowtext 2.25pt double; border-left: 0px; padding: 0in;"> 660,023 </td> <td style="height: 15.75pt; width: 11.25pt; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15.75pt; background: #cceeff; border-right: 0px; width: 10.5pt; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="border-top: 0px; height: 15.75pt; background: #cceeff; border-right: 0px; width: 65.25pt; border-bottom: windowtext 2.25pt double; border-left: 0px; padding: 0in;"> 468,756 </td> </tr> </table> </div>

448353

373224

59497

49901

30000

122173

45631

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> 6.         PATENT ACQUISITION OBLIGATION             On March 27, 2017, the Company issued 947,606 shares of common stock to Meetrix Communications, Inc. (“Meetrix”) in satisfaction of the obligation owed by us to Meetrix pursuant to the terms of the Patent Acquisition Agreement, dated November 11, 2013 between the Company and Meetrix.  The carrying value of the patent acquisition obligation at the date of extinguishment was approximately $4,400,000.  The fair value of the shares of common stock issued to satisfy the obligation on the date of extinguishment was approximately $2,843,000, resulting in the recognition of a gain on the debt extinguishment of approximately $1,548,000. </div>

947606

4400000

2843000

1548000

3500000

Pursuant to the Series A Redemption Terms, on December 9, 2016 the holder of the Series A Preferred received (i) $500,000 in cash, (ii) a 12% secured debenture evidencing the remaining $3,000,000 amount to be redeemed, $1,000,000 of which is due on or before June 1, 2017 and the remainder of which is due November 11, 2017 (the “Redemption Debenture”), and (iii) a 5 year warrant to purchase 500,000 shares of the Company’s common stock at an exercise price equal to 10% below the thirty (30) day volume weighted average closing price of our common stock at closing (the “Redemption Warrant”).

500000

0.12

3000000

1000000

P5Y

500000

0.10 2999000

2801000

792000 5508000

2008000

3155872

837400

3138472

707387

739958

3153472

837400

<table style="width: 550pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 31.5pt;"> <td style="height: 31.5pt; width: 82%; padding: 0in 5.4pt 0in 5.4pt; width: 82%;"> </td> <td style="height: 31.5pt; width: 2%; padding: 0in 5.4pt 0in 5.4pt; width: 2%;"> </td> <td style="border-top: 0px; height: 31.5pt; border-right: 0px; width: 16%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in 5.4pt 0in 5.4pt; width: 16%;" rowspan="2" valign="bottom">  For the Three Months Ended April 30, 2017 </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 82%; padding: 0in 5.4pt 0in 5.4pt; width: 82%;"> </td> <td style="height: 15.75pt; width: 2%; padding: 0in 5.4pt 0in 5.4pt; width: 2%;"> </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 82%; background: #cceeff; padding: 0in; width: 82%;" valign="bottom"> Basic weighted average common shares outstanding </td> <td style="height: 15.75pt; width: 2%; background: #cceeff; padding: 0in 5.4pt 0in 5.4pt; width: 2%;"> </td> <td style="height: 15.75pt; width: 16%; background: #cceeff; padding: 0in; width: 16%;" valign="bottom"> 9,734,171 </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 82%; padding: 0in; width: 82%;" valign="bottom"> Effect of stock options </td> <td style="height: 15.75pt; width: 2%; padding: 0in 5.4pt 0in 5.4pt; width: 2%;"> </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 16%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in; width: 16%;" valign="bottom"> 2,400 </td> </tr> <tr style="height: 16.5pt;"> <td style="height: 16.5pt; width: 82%; background: #cceeff; padding: 0in; width: 82%;" valign="bottom"> Dilutive weighted average common shares outstanding </td> <td style="height: 16.5pt; width: 2%; background: #cceeff; padding: 0in 5.4pt 0in 5.4pt; width: 2%;"> </td> <td style="border-top: 0px; height: 16.5pt; border-right: 0px; width: 16%; background: #cceeff; border-bottom: windowtext 2.25pt double; border-left: 0px; padding: 0in; width: 16%;" valign="bottom"> 9,736,571 </td> </tr> </table>

2400

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> 10.       INCOME TAXES We file Federal, New York, California and Pennsylvania state income tax returns.  Due to net operating losses, the statute of limitations for Federal and New York State income tax returns remains open to examination by taxing authorities since the fiscal year ended October 31, 1997.  We account for interest and penalties related to income tax matters, if any, in marketing, general and administrative expenses. There are no unrecognized income tax benefits as of April 30, 2017 and October 31, 2016. We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse.  A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have substantial net operating loss carryforwards for Federal and New York State income tax returns. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets. </div>

<div style="font-family: "Courier New"; font-size: 10pt; "> <a name="_DV_M197"></a>11.       COMMITMENT AND CONTINGENCES  Litigation Matters Other than suits we bring to enforce our patent rights we are not a party to any material pending legal proceedings other than that which arise in the ordinary course of business.  We believe that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on our financial position or results of operations. </div>

EX-101.SCH 7 itus-20170430.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - BUSINESS AND FUNDING link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - STOCK BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - INVESTMENTS link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - PATENT ACQUISITION OBLIGATION link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - PREFERRED STOCK REDEMPTION link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - COMMITMENT AND CONTINGENCES link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - BUSINESS AND FUNDING (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - STOCK BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - BUSINESS AND FUNDING (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - BUSINESS AND FUNDING (Details) - Significant balance sheet amounts affected by the offering link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - STOCK BASED COMPENSATION (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding the 2003 Share Plan link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under 2003 share plan link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding the 2010 Share Plan link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding under 2010 Share Plan link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding Stock options granted not under 2003 Share Plan and 2010 Share Plan link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding not under 2003 Share Plan and 2010 Share Plan link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - FAIR VALUE MEASUREMENTS (Details) - Changes in the fair value of the Company's Level 3 financial liabilities measured at fair value link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - INVESTMENTS (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - PATENT ACQUISITION OBLIGATION (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - PREFERRED STOCK REDEMPTION (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) - Reconciliation between basic weighted average common shares outstanding and dilutive weighted average common shares outstanding link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 itus-20170430_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 itus-20170430_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 itus-20170430_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Statement of Financial Position [Abstract] Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Short-term investments in certificates of deposit Prepaid expenses and other current assets Total current assets Patents, net of accumulated amortization of $1,127,688 and $965,040, respectively Patents, accumulated amortization (in Dollars) Property and equipment, net of accumulated depreciation of $68,228 and $46,950, respectively Property and equipment, accumulated depreciation (in Dollars) Total assets Total assets Accounts payable and accrued expenses Total Secured debenture (Note 7) Total current liabilities Patent acquisition obligation Patent Acquisition Obligation Total liabilities Commitments and contingencies (Note 11) Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; -0- and 140 shares issued and outstanding, respectively Equity Interest Type [Axis] Preferred Stock [Member] Preferred stock par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Class of Stock [Axis] Series A Preferred Stock [Member] Common stock par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Total shareholders’ equity Balance Balance Total shareholders’ equity Total liabilities and shareholders’ equity Income Statement [Abstract] Revenue Litigation and licensing expenses Amortization of patents Amortization of Intangible Assets Research and development expenses (including non-cash stock option compensation expenses of $68,928, $72,496, $148,628 and $91,442, respectively) Income Statement Location [Axis] Research and Development Expense [Member] Non-cash Stock Option Compensation Expenses Marketing, general and administrative expenses (including non-cash stock option compensation expenses of $122,991, $144,758, $303,028 and $238,307, respectively) Selling and Marketing Expense [Member] Total operating costs and expenses Loss from operations Gain on extinguishment of patent acquisition obligation (Note 6) Gain on extinguishment of patent acquisition obligation Gain (Loss) on Extinguishment of Debt Interest expense Interest income Income (loss) before income taxes Provision for income taxes Net income (loss) Net loss Deemed dividend to preferred stockholder (Note 7) Net loss attributable to common stockholders Basic (in Dollars per share) Diluted (in Dollars per share) Basic and diluted (in Dollars per share) Basic (in Shares) Basic weighted average common shares outstanding Diluted (in Shares) Dilutive weighted average common shares outstanding Basic and diluted (in Shares) Statement of Stockholders' Equity [Abstract] Balance (in Shares) Balance (in Shares) Stock option compensation to employees and directors Common stock issued upon exercise of stock options Common stock issued upon exercise of stock options (in Shares) Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Common stock issued to consultants Common stock issued to consultants (in Shares) Stock Issued During Period, Shares, Issued for Services Redemption of convertible preferred stock (Note 7) Redemption of convertible preferred stock (Note 7) (in Shares) Common stock issued to repay patent acquisition obligation (Note 6) Common stock issued to repay patent acquisition obligation (Note 6) (in Shares) Common stock issued in shareholder rights offering Common stock issued in shareholder rights offering (in Shares) Stock Issued During Period, Shares, New Issues (in Shares) Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Statement of Cash Flows [Abstract] Stock option compensation to employees and directors Common stock issued to consultants Depreciation of property and equipment Accretion of interest on patent acquisition obligations to interest expense Accrued interest on secured debenture Common stock issued to acquire patent license Prepaid expenses and other current assets Accounts payable and accrued expenses Royalties and contingent legal fees payable Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Disbursements to acquire short-term investments in certificates of deposit Payments to Acquire Short-term Investments Proceeds from maturities of short-term investments in certificates of deposit Proceeds from Sale of Short-term Investments Payments for purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Redemption of convertible preferred stock Redemption Of Convertible Preferred Stock Proceeds from sale of common stock through a rights offering to shareholders Proceeds from Issuance of Common Stock Proceeds from exercise of employee stock options Proceeds from Stock Options Exercised Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash and cash equivalents Redemption of Series A convertible preferred stock into secured debenture (Note 7) Common stock issued to pay patent acquisition obligation (Note 6) Accounting Policies [Abstract] Significant balance sheet amounts affected by the offering [Abstract] Sale of Stock [Axis] Registered Public Offering [Member] Cash, cash equivalents and short term investments Cash, Cash Equivalents, and Short-term Investments Subsequent Event Type [Axis] Subsequent Event [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Plan Name [Axis] 2003 Share Plan [Member] Information regarding the 2003 Share Plan [Abstract] Options Outstanding at October 31, 2016 Options Outstanding at April 30, 2017 Options Outstanding at October 31, 2016 Options Outstanding at April 30, 2017 Exercised Forfeited Forfeited Options Outstanding and exercisable at April 30, 2017 Options Outstanding and exercisable at April 30, 2017 Options Outstanding and exercisable at April 30, 2017 Stock options outstanding and exercisable under 2003 share plan [Abstract] Exercise Price Range [Axis] Range Of Exercise Prices $1.79 To $7.75 [Member] Options Outstanding and Exercisable, Number Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share) Options Outstanding and Exercisable, Weighted Average Exercise Price Range Of Exercise Prices $13.50 To $17.50 [Member] Range Of Exercise Prices $18.75 To $23.00 [Member] Range Of Exercise Prices $29.25 [Member] 2010 Share Plan [Member] Information regarding the 2010 Share Plan [Abstract] Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options Outstanding at April 30, 2017 Options Exercisable at April 30, 2017 Options Exercisable at April 30, 2017 Options Exercisable at April 30, 2017 Stock options outstanding under 2010 Share Plan [Abstract] Range Of Exercise Prices $2.58 To $9.25 [Member] Options Outstanding, Number Options Outstanding,Weighted Average Remaining Contractual Life Options Outstanding, Weighted Average Exercise Price Options Exercisable, Number Options Exercisable,Weighted Average Remaining Contractual Life Options Exercisable, Weighted Average Exercise Price Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] Information regarding Stock options granted not under 2003 Share Plan and 2010 Share Plan [Abstract] Stock options outstanding not under 2003 Share Plan and 2010 Share Plan [Abstract] Range Of Exercise Prices $2.58 To $5.56 [Member] Fair Value Disclosures [Abstract] Hierarchy for financial assets measured at fair value [Abstract] Asset Class [Axis] Cash Equivalents [Member] Financial assets Certificates of Deposit [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Hierarchy for financial liabilities measured at fair value [Abstract] Patent Acquisition Obligation [Member] Financial Liability Changes in the fair value of the Company's Level 3 financial liabilities measured at fair value [Abstract] Balance October 31, 2016 Balance April 30, 2017 Accreted interest on patent obligation Extinguishment of patent obligation Investments Schedule [Abstract] Payables and Accruals [Abstract] Accounts payable and accrued expense [Abstract] Accounts payable Payroll and related expenses Accrued interest on secured debenture Accrued other Patent Acquisition Obligation [Abstract] Disclosure Text Block Supplement [Abstract] Earnings Per Share [Abstract] Net income (loss) per common share: Reconciliation between basic weighted average common shares outstanding and dilutive weighted average common shares outstanding [Abstract] Effect of stock options New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Income Tax Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] EX-101.PRE 11 itus-20170430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Apr. 30, 2017	May 25, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ITUS CORPORATION
Document Type	10-Q
Current Fiscal Year End Date	--10-31
Entity Common Stock, Shares Outstanding		15,120,239
Amendment Flag	false
Entity Central Index Key	0000715446
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Apr. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Apr. 30, 2017	Oct. 31, 2016
Current assets:
Cash and cash equivalents	$ 2,876,897	$ 2,488,323
Short-term investments in certificates of deposit	2,250,000	750,000
Prepaid expenses and other current assets	64,647	162,069
Total current assets	5,191,544	3,400,392
Patents, net of accumulated amortization of $1,127,688 and $965,040, respectively	1,908,423	2,071,071
Property and equipment, net of accumulated depreciation of $68,228 and $46,950, respectively	149,487	156,644
Total assets	7,249,454	5,628,107
Current liabilities:
Accounts payable and accrued expenses	660,023	468,756
Secured debenture (Note 7)	3,000,000
Total current liabilities	3,660,023	468,756
Patent acquisition obligation		4,171,876
Total liabilities	3,660,023	4,640,632
Commitments and contingencies (Note 11)
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; -0- and 140 shares issued and outstanding, respectively		14,000
Common stock, par value $.01 per share; 24,000,000 shares authorized; 11,694,863 and 8,752,387 shares issued and outstanding, respectively	116,949	87,524
Additional paid-in capital	156,066,446	152,051,144
Accumulated deficit	(152,593,964)	(151,165,193)
Total shareholders’ equity	3,589,431	987,475
Total liabilities and shareholders’ equity	7,249,454	5,628,107
Series A Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; -0- and 140 shares issued and outstanding, respectively		14,000
Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; -0- and 140 shares issued and outstanding, respectively

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Apr. 30, 2017	Oct. 31, 2016
Patents, accumulated amortization (in Dollars)	$ 1,127,688	$ 965,040
Property and equipment, accumulated depreciation (in Dollars)	$ 68,228	$ 46,950
Common stock par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	24,000,000	24,000,000
Common stock, shares issued	11,694,863	8,752,387
Common stock, shares outstanding	11,694,863	8,752,387
Series A Preferred Stock [Member]
Preferred stock par value (in Dollars per share)	$ 100	$ 100
Preferred stock, shares authorized	140	140
Preferred stock, shares issued	0	140
Preferred stock, shares outstanding	0	140
Preferred Stock [Member]
Preferred stock par value (in Dollars per share)	$ 100	$ 100
Preferred stock, shares authorized	19,860	19,860
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Revenue
Operating costs and expenses:
Litigation and licensing expenses	225	15,521	2,346	75,162
Amortization of patents	81,324	81,324	162,648	162,648
Research and development expenses (including non-cash stock option compensation expenses of $68,928, $72,496, $148,628 and $91,442, respectively)	431,124	392,589	882,754	850,910
Marketing, general and administrative expenses (including non-cash stock option compensation expenses of $122,991, $144,758, $303,028 and $238,307, respectively)	699,345	658,953	1,559,230	1,532,106
Total operating costs and expenses	1,212,018	1,148,387	2,606,978	2,620,826
Loss from operations	(1,212,018)	(1,148,387)	(2,606,978)	(2,620,826)
Gain on extinguishment of patent acquisition obligation (Note 6)	1,547,608		1,547,608
Interest expense	(175,727)	(126,980)	(371,026)	(250,881)
Interest income	626	3,473	1,625	6,724
Income (loss) before income taxes	160,489	(1,271,894)	(1,428,771)	(2,864,983)
Provision for income taxes
Net income (loss)	160,489	(1,271,894)	(1,428,771)	(2,864,983)
Deemed dividend to preferred stockholder (Note 7)			(2,008,775)
Net loss attributable to common stockholders	$ 160,489	$ (1,271,894)	$ (3,437,546)	$ (2,864,983)
Net income (loss) per common share:
Basic (in Dollars per share)	$ 0.02	$ (0.15)
Diluted (in Dollars per share)	0.02	(0.15)
Basic and diluted (in Dollars per share)			$ (0.37)	$ (0.33)
Weighted average common shares outstanding:
Basic (in Shares)	9,734,171	8,736,024
Diluted (in Shares)	9,736,571	8,736,024
Basic and diluted (in Shares)			9,236,351	8,731,489

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parentheticals) - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Research and Development Expense [Member]
Non-cash Stock Option Compensation Expenses	$ 68,928	$ 72,496	$ 148,628	$ 91,442
Selling and Marketing Expense [Member]
Non-cash Stock Option Compensation Expenses	$ 122,991	$ 144,758	$ 303,028	$ 238,307

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) - 6 months ended Apr. 30, 2017 - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Oct. 31, 2016	$ 14,000	$ 87,524	$ 152,051,144	$ (151,165,193)	$ 987,475
Balance (in Shares) at Oct. 31, 2016	140	8,752,387
Stock option compensation to employees and directors			451,655		451,655
Common stock issued upon exercise of stock options		$ 22	5,643		5,665
Common stock issued upon exercise of stock options (in Shares)		2,200
Common stock issued to consultants		$ 35	17,776		17,811
Common stock issued to consultants (in Shares)		3,463
Redemption of convertible preferred stock (Note 7)	$ (14,000)		(3,486,000)		(3,500,000)
Redemption of convertible preferred stock (Note 7) (in Shares)	(140)
Common stock issued to repay patent acquisition obligation (Note 6)		$ 9,476	2,842,818		2,852,294
Common stock issued to repay patent acquisition obligation (Note 6) (in Shares)		947,606
Common stock issued in shareholder rights offering		$ 19,892	4,183,410		4,203,302
Common stock issued in shareholder rights offering (in Shares)		1,989,207
Net loss				(1,428,771)	(1,428,771)
Balance at Apr. 30, 2017		$ 116,949	$ 156,066,446	$ (152,593,964)	$ 3,589,431
Balance (in Shares) at Apr. 30, 2017		11,694,863

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (1,428,771)	$ (2,864,983)
Stock option compensation to employees and directors	451,655	329,749
Common stock issued to consultants	17,811	11,361
Depreciation of property and equipment	21,278	13,881
Amortization of patents	162,648	162,648
Accretion of interest on patent acquisition obligations to interest expense	228,026	250,881
Accrued interest on secured debenture	30,000
Gain on extinguishment of patent acquisition obligation	(1,547,608)
Common stock issued to acquire patent license		11,800
Change in operating assets and liabilities:
Prepaid expenses and other current assets	97,422	87,496
Accounts payable and accrued expenses	161,267	132,031
Royalties and contingent legal fees payable		(18,883)
Net cash used in operating activities	(1,806,272)	(1,884,019)
Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit	(2,250,000)	(1,550,000)
Proceeds from maturities of short-term investments in certificates of deposit	750,000	1,800,000
Payments for purchases of property and equipment	(14,121)	(141,110)
Net cash (used in) provided by investing activities	(1,514,121)	108,890
Cash flows from financing activities:
Redemption of convertible preferred stock	(500,000)
Proceeds from sale of common stock through a rights offering to shareholders	4,203,302
Proceeds from exercise of employee stock options	5,665	18,231
Net cash provided by financing activities	3,708,967	18,231
Net increase (decrease) in cash and cash equivalents	388,574	(1,756,898)
Cash and cash equivalents at beginning of period	2,488,323	4,369,219
Cash and cash equivalents at end of period	2,876,897	2,612,321
Supplemental disclosure of non-cash financing activities:
Redemption of Series A convertible preferred stock into secured debenture (Note 7)	(3,000,000)
Common stock issued to pay patent acquisition obligation (Note 6)	$ (4,399,902)

XML 19 R8.htm IDEA: XBRL DOCUMENT

BUSINESS AND FUNDING

6 Months Ended

Apr. 30, 2017

Accounting Policies [Abstract]

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]

1. BUSINESS AND FUNDING

Description of Business

Funding and Management’s Plans

Subsequent Event

As of May 25, 2017, significant balance sheet amounts affected by this offering are approximately as follows:

Cash, cash equivalents and short term investments	$	8,104,000
Total assets	$	10,227,000
Total shareholders’ equity	$	6,567,000

Basis of Presentation

Revenue Recognition

Patent Licensing

Intangible Assets

XML 20 R9.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION

6 Months Ended

Apr. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

2. STOCK BASED COMPENSATION

Stock Option Compensation Expense

Stock Option Activity

Stock Option Plans

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2016	225,600	$	18.69
Exercised	(2,200)	$	2.58
Forfeited	(34,400)	$	17.85
Options Outstanding and exercisable at April 30, 2017	189,000	$	19.03	$	390

The following table summarizes information about stock options outstanding and exercisable under the 2003 Share Plan as of April 30, 2017:

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$1.79 - $7.75	39,000	1.32	$	2.92
$13.50 - $17.50	21,400	.45	$	16.46
$18.75 - $23.00	88,600	.37	$	22.13
$29.25	40,000	.31	$	29.25

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2016	1,080,872	$	3.12
Granted	106,000	$	5.00
Options Outstanding at April 30, 2017	1,186,872	$	3.29	$	-
Options Exercisable at April 30, 2017	793,994	$	3.15	$	-

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2017:

	Options Outstanding				Options Exercisable
		Weighted Average Remaining Contractual Life (in years)				Weighted Average Remaining Contractual Life (in years)
								Weighted Average Exercise Price
				Weighted Average Exercise Price
Range of Exercise Prices	Number Outstanding				Number Exercisable
Range of Exercise Prices	Number Outstanding				Number Exercisable

$2.58 - $9.25	1,186,872	7.42	$	3.29	793,994	6.65	$	3.15
								.

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2016	1,780,000	$	2.70
Options Outstanding and exercisable at April 30, 2017	1,780,000	$	2.70	$	-

The following table summarizes information about stock options outstanding and exercisable that were not granted under the 2003 Share Plan or the 2010 Share Plan as of April 30, 2017:

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$2.58 - $5.56	1,780,000	5.26	$	2.70
				.

Stock Awards

XML 21 R10.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS

6 Months Ended

Apr. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

3. FAIR VALUE MEASUREMENTS

Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of April 30, 2017:

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	2,585,760	$	-	$	-	$	2,585,760
Certificates of deposit – Short-term investments		-		2,250,000		-		2,250,000
Total financial assets	$	2,585,760	$	2,250,000	$	-	$	4,835,760

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2016:

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	1,899,136	$	-	$	-	$	1,899,136
Certificates of deposit – Short-term investments		-		750,000		-		750,000
Total financial assets	$	1,899,136	$	750,000	$	-	$	2,649,136

	Level 1		Level 2		Level 3		Total

Patent acquisition obligation	$	-	$	-	$	-	$	-

	Level 1		Level 2		Level 3		Total

Patent acquisition obligation	$	-	$	-	$	4,171,876	$	4,171,876

The following table sets forth the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:


Patent acquisition obligation
Balance October 31, 2016	$	4,171,876
Accreted interest on patent obligation		228,026
Extinguishment of patent obligation		(4,399,902)
Balance April 30, 2017	$	-

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

INVESTMENTS	6 Months Ended
INVESTMENTS	Apr. 30, 2017
Investments Schedule [Abstract]
Investment [Text Block]	4. INVESTMENTS At April 30, 2017 and October 31, 2016, we had certificates of deposit of $2,250,000 and $750,000, respectively, which were classified as short-term investments and reported at fair value.

XML 23 R12.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

6 Months Ended

Apr. 30, 2017

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expense consist of the following as of:

	April 30, 2017		October 31, 2016
	April 30, 2017		October 31, 2016
Accounts payable	$	448,353	$	373,224
Payroll and related expenses		59,497		49,901
Accrued interest on secured debenture		30,000		-
Accrued other		122,173		45,631
Total	$	660,023	$	468,756

XML 24 R13.htm IDEA: XBRL DOCUMENT

PATENT ACQUISITION OBLIGATION	6 Months Ended
PATENT ACQUISITION OBLIGATION	Apr. 30, 2017
Patent Acquisition Obligation [Abstract]
Patent Acquisition Obligation [Text Block]	6. PATENT ACQUISITION OBLIGATION On March 27, 2017, the Company issued 947,606 shares of common stock to Meetrix Communications, Inc. (“Meetrix”) in satisfaction of the obligation owed by us to Meetrix pursuant to the terms of the Patent Acquisition Agreement, dated November 11, 2013 between the Company and Meetrix. The carrying value of the patent acquisition obligation at the date of extinguishment was approximately $4,400,000. The fair value of the shares of common stock issued to satisfy the obligation on the date of extinguishment was approximately $2,843,000, resulting in the recognition of a gain on the debt extinguishment of approximately $1,548,000.

XML 25 R14.htm IDEA: XBRL DOCUMENT

PREFERRED STOCK REDEMPTION	6 Months Ended
PREFERRED STOCK REDEMPTION	Apr. 30, 2017
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	7. PREFERRED STOCK REDEMPTION On November 11, 2016, the holder of all our outstanding Series A Preferred with an aggregate stated value of $3,500,000 exercised its right of redemption to receive such amount from proceeds from the sale of the Company’s equity securities. On December 6, 2016, we entered into an agreement with the holder of the Series A Preferred setting forth the terms under which such redemption would take place (the “Series A Redemption Terms”). Pursuant to the Series A Redemption Terms, on December 9, 2016 the holder of the Series A Preferred received (i) $500,000 in cash, (ii) a 12% secured debenture evidencing the remaining $3,000,000 amount to be redeemed, $1,000,000 of which is due on or before June 1, 2017 and the remainder of which is due November 11, 2017 (the “Redemption Debenture”), and (iii) a 5 year warrant to purchase 500,000 shares of the Company’s common stock at an exercise price equal to 10% below the thirty (30) day volume weighted average closing price of our common stock at closing (the “Redemption Warrant”). The Redemption Debenture is secured by a lien on the Company’s assets and prohibits the Company from incurring any senior indebtedness other than equipment financing in connection with the Company’s business. The difference between the fair value of the consideration given to the holder of our Series A Preferred and the carrying value of the Series A Preferred represents a return to the preferred stockholder which is treated in a similar manner as that of dividends paid on preferred stock. In the redemption, the Series A Preferred holder received $500,000 in cash, the Redemption Debenture with a present value of approximately $2,999,000 and the Redemption Warrant with a fair value of approximately $2,801,000, determined using the Black Scholes pricing model, and waived the Series A Preferred’s conversion right with an intrinsic value of approximately $792,000, resulting in total consideration given to the Series A Preferred holder of approximately $5,508,000. The difference between the fair value of the consideration and the $3,500,000 carrying value of the Series A Preferred resulted in a deemed dividend to the Series A Preferred holder of approximately $2,008,000.

XML 26 R15.htm IDEA: XBRL DOCUMENT

NET INCOME (LOSS) PER SHARE OF COMMON STOCK

6 Months Ended

Apr. 30, 2017

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

8. NET INCOME (LOSS) PER SHARE OF COMMON STOCK

		For the Three Months Ended April 30, 2017
		For the Three Months Ended April 30, 2017
Basic weighted average common shares outstanding		9,734,171
Effect of stock options		2,400
Dilutive weighted average common shares outstanding		9,736,571

XML 27 R16.htm IDEA: XBRL DOCUMENT

EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	6 Months Ended
EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	Apr. 30, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	9. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers. This amendment updates addressing revenue from contracts with customers, which clarifies existing accounting literature relating to how and when a company recognizes revenue. Under the standard, a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. This standard update was effective for interim and annual reporting periods beginning after December 15, 2016, and were to be applied retrospectively or the cumulative effect as of the date of adoption, with early application not permitted. In July 2015, a one-year deferral of the effective date of the new guidance was approved. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is currently ongoing. In August 2014, the FASB issued Accounting Standards Update 2014-15 (“ASU 2014-15”). This amendment requires management to assess an entity’s ability to continue as a going concern every reporting period including interim periods, and to provide related footnote disclosure in certain circumstances. Adoption of this standard is required for annual periods ending after December 15, 2016 and are to be applied retrospectively or the cumulative effect as of the date of adoption. The adoption of this amendment on November 1, 2016 did not have an impact on our consolidated financial statements and related disclosures. In November 2015, the FASB issued Accounting Standards Update 2015-17 (“ASU 2015-17”) to simplify the presentation of deferred taxes. This amendment requires that all deferred tax assets and liabilities, along with any related valuation allowances, be classified as noncurrent on the balance sheet. Adoption of this standard is required for annual periods beginning after December 15, 2016. The adoption of this amendment on November 1, 2016 did not have an impact on our consolidated financial statements and related disclosures. In February 2016, the FASB issued Accounting Standards Update 2016-02 (“ASU 2016-02”) which requires lessees to recognize most leases on the balance sheet. This is expected to increase both reported assets and liabilities. The new lease standard does not substantially change lessor accounting. For public companies, the standard will be effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption is permitted. Lessees and lessors will be required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance, using a modified retrospective transition method. The requirements of this standard include a significant increase in required disclosures. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is ongoing. In March 2016, the FASB issued Accounting Standards Update 2016-09 (“ASU 2016-09”) that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election for forfeitures as they occur. The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those years. Early adoption is permitted. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is ongoing. In May 2017, the FASB issued Accounting Standards Update 2017-09 (“ASU 2017-09”) that provides guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting. This update is effective for all entities for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is ongoing.

XML 28 R17.htm IDEA: XBRL DOCUMENT

INCOME TAXES	6 Months Ended
INCOME TAXES	Apr. 30, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	10. INCOME TAXES We file Federal, New York, California and Pennsylvania state income tax returns. Due to net operating losses, the statute of limitations for Federal and New York State income tax returns remains open to examination by taxing authorities since the fiscal year ended October 31, 1997. We account for interest and penalties related to income tax matters, if any, in marketing, general and administrative expenses. There are no unrecognized income tax benefits as of April 30, 2017 and October 31, 2016. We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have substantial net operating loss carryforwards for Federal and New York State income tax returns. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets.

XML 29 R18.htm IDEA: XBRL DOCUMENT

COMMITMENT AND CONTINGENCES	6 Months Ended
COMMITMENT AND CONTINGENCES	Apr. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	11. COMMITMENT AND CONTINGENCES Litigation Matters Other than suits we bring to enforce our patent rights we are not a party to any material pending legal proceedings other than that which arise in the ordinary course of business. We believe that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on our financial position or results of operations.

XML 30 R19.htm IDEA: XBRL DOCUMENT

BUSINESS AND FUNDING (Tables)

6 Months Ended

Apr. 30, 2017

Accounting Policies [Abstract]

Schedule of Amounts Affected in Balance Sheet Due to Public Offering [Table Text Block]

Cash, cash equivalents and short term investments	$	8,104,000
Total assets	$	10,227,000
Total shareholders’ equity	$	6,567,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Tables)

6 Months Ended

Apr. 30, 2017

2003 Share Plan [Member]

STOCK BASED COMPENSATION (Tables) [Line Items]

Share-based Compensation, Stock Options, Activity [Table Text Block]

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2016	225,600	$	18.69
Exercised	(2,200)	$	2.58
Forfeited	(34,400)	$	17.85
Options Outstanding and exercisable at April 30, 2017	189,000	$	19.03	$	390

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$1.79 - $7.75	39,000	1.32	$	2.92
$13.50 - $17.50	21,400	.45	$	16.46
$18.75 - $23.00	88,600	.37	$	22.13
$29.25	40,000	.31	$	29.25

2010 Share Plan [Member]

STOCK BASED COMPENSATION (Tables) [Line Items]

Share-based Compensation, Stock Options, Activity [Table Text Block]

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2016	1,080,872	$	3.12
Granted	106,000	$	5.00
Options Outstanding at April 30, 2017	1,186,872	$	3.29	$	-
Options Exercisable at April 30, 2017	793,994	$	3.15	$	-

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

	Options Outstanding				Options Exercisable
		Weighted Average Remaining Contractual Life (in years)				Weighted Average Remaining Contractual Life (in years)
								Weighted Average Exercise Price
				Weighted Average Exercise Price
Range of Exercise Prices	Number Outstanding				Number Exercisable
Range of Exercise Prices	Number Outstanding				Number Exercisable

$2.58 - $9.25	1,186,872	7.42	$	3.29	793,994	6.65	$	3.15
								.

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member]

STOCK BASED COMPENSATION (Tables) [Line Items]

Share-based Compensation, Stock Options, Activity [Table Text Block]

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2016	1,780,000	$	2.70
Options Outstanding and exercisable at April 30, 2017	1,780,000	$	2.70	$	-

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$2.58 - $5.56	1,780,000	5.26	$	2.70
				.

XML 32 R21.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Apr. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	2,585,760	$	-	$	-	$	2,585,760
Certificates of deposit – Short-term investments		-		2,250,000		-		2,250,000
Total financial assets	$	2,585,760	$	2,250,000	$	-	$	4,835,760

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	1,899,136	$	-	$	-	$	1,899,136
Certificates of deposit – Short-term investments		-		750,000		-		750,000
Total financial assets	$	1,899,136	$	750,000	$	-	$	2,649,136

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

	Level 1		Level 2		Level 3		Total

Patent acquisition obligation	$	-	$	-	$	-	$	-

	Level 1		Level 2		Level 3		Total

Patent acquisition obligation	$	-	$	-	$	4,171,876	$	4,171,876

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]


Patent acquisition obligation
Balance October 31, 2016	$	4,171,876
Accreted interest on patent obligation		228,026
Extinguishment of patent obligation		(4,399,902)
Balance April 30, 2017	$	-

XML 33 R22.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

6 Months Ended

Apr. 30, 2017

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

	April 30, 2017		October 31, 2016
	April 30, 2017		October 31, 2016
Accounts payable	$	448,353	$	373,224
Payroll and related expenses		59,497		49,901
Accrued interest on secured debenture		30,000		-
Accrued other		122,173		45,631
Total	$	660,023	$	468,756

XML 34 R23.htm IDEA: XBRL DOCUMENT

NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Tables)

6 Months Ended

Apr. 30, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		For the Three Months Ended April 30, 2017
		For the Three Months Ended April 30, 2017
Basic weighted average common shares outstanding		9,734,171
Effect of stock options		2,400
Dilutive weighted average common shares outstanding		9,736,571

XML 35 R24.htm IDEA: XBRL DOCUMENT

BUSINESS AND FUNDING (Details) - USD ($)		3 Months Ended		6 Months Ended
BUSINESS AND FUNDING (Details) - USD ($)	May 16, 2017	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	May 25, 2017	Oct. 31, 2016
BUSINESS AND FUNDING (Details) [Line Items]
Net Cash Provided by (Used in) Operating Activities				$ (1,806,272)	$ (1,884,019)
Net Cash Provided by (Used in) Investing Activities				(1,514,121)	108,890
Payments to Acquire Short-term Investments				2,250,000	1,550,000
Proceeds from Sale of Short-term Investments				750,000	1,800,000
Payments to Acquire Property, Plant, and Equipment				14,121	141,110
Net Cash Provided by (Used in) Financing Activities				3,708,967	18,231
Proceeds from Issuance of Common Stock				4,203,302
Redemption Of Convertible Preferred Stock				500,000
Cash, Period Increase (Decrease)				1,889,000
Cash, Cash Equivalents, and Short-term Investments		$ 5,127,000		5,127,000			$ 3,238,000
Amortization of Intangible Assets		$ 81,324	$ 81,324	$ 162,648	$ 162,648
Subsequent Event [Member] \| Registered Public Offering [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Proceeds from Issuance of Common Stock	$ 3,214,000
Cash, Cash Equivalents, and Short-term Investments						$ 8,104,000
Stock Issued During Period, Shares, New Issues (in Shares)	3,425,376

XML 36 R25.htm IDEA: XBRL DOCUMENT

BUSINESS AND FUNDING (Details) - Significant balance sheet amounts affected by the offering - USD ($)	May 25, 2017	Apr. 30, 2017	Oct. 31, 2016
BUSINESS AND FUNDING (Details) - Significant balance sheet amounts affected by the offering [Line Items]
Cash, cash equivalents and short term investments		$ 5,127,000	$ 3,238,000
Total assets		7,249,454	5,628,107
Total shareholders’ equity		$ 3,589,431	$ 987,475
Subsequent Event [Member] \| Registered Public Offering [Member]
BUSINESS AND FUNDING (Details) - Significant balance sheet amounts affected by the offering [Line Items]
Cash, cash equivalents and short term investments	$ 8,104,000
Total assets	10,227,000
Total shareholders’ equity	$ 6,567,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - USD ($)	3 Months Ended		6 Months Ended
STOCK BASED COMPENSATION (Details) - USD ($)	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
STOCK BASED COMPENSATION (Details) [Line Items]
Proceeds from Stock Options Exercised			$ 5,665	$ 18,231
2010 Share Plan [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			106,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 5.00
Employee Stock Option [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation	$ 192,000	$ 217,000	$ 452,000	$ 330,000
Employee Stock Option [Member] \| 2010 Share Plan [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			106,000	545,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 5.00	$ 2.92
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			2,200	7,080
Proceeds from Stock Options Exercised			$ 6,000	$ 18,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	764,000		764,000
Employee Stock Option [Member] \| Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,780,000
Employee Stock Option [Member] \| Minimum [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			1 year
Employee Stock Option [Member] \| Maximum [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			10 years
Employee Stock Option [Member] \| Consultant [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services			3,463	3,701
Consultation Expense			$ 18,000	$ 11,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Information regarding the 2003 Share Plan - 2003 Share Plan [Member]	6 Months Ended
	Apr. 30, 2017 USD ($) $ / shares shares
STOCK BASED COMPENSATION (Details) - Information regarding the 2003 Share Plan [Line Items]
Options Outstanding at October 31, 2016 \| shares	225,600
Options Outstanding at October 31, 2016 \| $ / shares	$ 18.69
Exercised \| shares	(2,200)
Exercised \| $ / shares	$ 2.58
Forfeited \| shares	(34,400)
Forfeited \| $ / shares	$ 17.85
Options Outstanding and exercisable at April 30, 2017 \| shares	189,000
Options Outstanding and exercisable at April 30, 2017 \| $ / shares	$ 19.03
Options Outstanding and exercisable at April 30, 2017 \| $	$ 390

XML 39 R28.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under 2003 share plan - 2003 Share Plan [Member]	6 Months Ended
	Apr. 30, 2017 $ / shares shares
Range Of Exercise Prices $1.79 To $7.75 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding and Exercisable, Number \| shares	39,000
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life	1 year 116 days
Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 2.92
Range Of Exercise Prices $13.50 To $17.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding and Exercisable, Number \| shares	21,400
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life	164 days
Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 16.46
Range Of Exercise Prices $18.75 To $23.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding and Exercisable, Number \| shares	88,600
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life	135 days
Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 22.13
Range Of Exercise Prices $29.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding and Exercisable, Number \| shares	40,000
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life	113 days
Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 29.25

XML 40 R29.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Information regarding the 2010 Share Plan - 2010 Share Plan [Member]	6 Months Ended
	Apr. 30, 2017 USD ($) $ / shares shares
STOCK BASED COMPENSATION (Details) - Information regarding the 2010 Share Plan [Line Items]
Options Outstanding at October 31, 2016 \| shares	1,080,872
Options Outstanding at October 31, 2016 \| $ / shares	$ 3.12
Granted \| shares	106,000
Granted \| $ / shares	$ 5.00
Options Outstanding at April 30, 2017 \| shares	1,186,872
Options Outstanding at April 30, 2017 \| $ / shares	$ 3.29
Options Outstanding at April 30, 2017 \| $
Options Exercisable at April 30, 2017 \| shares	793,994
Options Exercisable at April 30, 2017 \| $ / shares	$ 3.15
Options Exercisable at April 30, 2017 \| $

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Stock options outstanding under 2010 Share Plan - 2010 Share Plan [Member] - Range Of Exercise Prices $2.58 To $9.25 [Member]	6 Months Ended
	Apr. 30, 2017 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number \| shares	1,186,872
Options Outstanding,Weighted Average Remaining Contractual Life	7 years 153 days
Options Outstanding, Weighted Average Exercise Price \| $ / shares	$ 3.29
Options Exercisable, Number \| shares	793,994
Options Exercisable,Weighted Average Remaining Contractual Life	6 years 237 days
Options Exercisable, Weighted Average Exercise Price \| $ / shares	$ 3.15

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Information regarding Stock options granted not under 2003 Share Plan and 2010 Share Plan - Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member]	Apr. 30, 2017 USD ($) $ / shares shares
STOCK BASED COMPENSATION (Details) - Information regarding Stock options granted not under 2003 Share Plan and 2010 Share Plan [Line Items]
Options Outstanding at October 31, 2016 \| shares	1,780,000
Options Outstanding at October 31, 2016 \| $ / shares	$ 2.70
Options Outstanding and exercisable at April 30, 2017 \| shares	1,780,000
Options Outstanding and exercisable at April 30, 2017 \| $ / shares	$ 2.70
Options Outstanding and exercisable at April 30, 2017 \| $

XML 43 R32.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Stock options outstanding not under 2003 Share Plan and 2010 Share Plan - Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] - Range Of Exercise Prices $2.58 To $5.56 [Member]	6 Months Ended
	Apr. 30, 2017 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding and Exercisable, Number \| shares	1,780,000
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life	5 years 94 days
Options Outstanding and Exercisable, Weighted Average Exercise Price \| $ / shares	$ 2.70

XML 44 R33.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value - USD ($)	Apr. 30, 2017	Oct. 31, 2016
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	$ 4,835,760	$ 2,649,136
Fair Value, Inputs, Level 1 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,585,760	1,899,136
Fair Value, Inputs, Level 2 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,250,000	750,000
Fair Value, Inputs, Level 3 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets
Cash Equivalents [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,585,760	1,899,136
Cash Equivalents [Member] \| Fair Value, Inputs, Level 1 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,585,760	1,899,136
Cash Equivalents [Member] \| Fair Value, Inputs, Level 2 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets
Cash Equivalents [Member] \| Fair Value, Inputs, Level 3 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets
Certificates of Deposit [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,250,000	750,000
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 1 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 2 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,250,000	750,000
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 3 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets

XML 45 R34.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value - Patent Acquisition Obligation [Member] - USD ($)	Apr. 30, 2017	Oct. 31, 2016
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value [Line Items]
Financial Liability		$ 4,171,876
Fair Value, Inputs, Level 1 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value [Line Items]
Financial Liability
Fair Value, Inputs, Level 2 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value [Line Items]
Financial Liability
Fair Value, Inputs, Level 3 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value [Line Items]
Financial Liability		$ 4,171,876

XML 46 R35.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Details) - Changes in the fair value of the Company's Level 3 financial liabilities measured at fair value	6 Months Ended
	Apr. 30, 2017 USD ($)
Changes in the fair value of the Company's Level 3 financial liabilities measured at fair value [Abstract]
Balance October 31, 2016	$ 4,171,876
Accreted interest on patent obligation	228,026
Extinguishment of patent obligation	(4,399,902)
Balance April 30, 2017

XML 47 R36.htm IDEA: XBRL DOCUMENT

INVESTMENTS (Details) - USD ($)	Apr. 30, 2017	Oct. 31, 2016
Investments Schedule [Abstract]
Certificates of Deposit, at Carrying Value	$ 2,250,000	$ 750,000

XML 48 R37.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense - USD ($)	Apr. 30, 2017	Oct. 31, 2016
Accounts payable and accrued expense [Abstract]
Accounts payable	$ 448,353	$ 373,224
Payroll and related expenses	59,497	49,901
Accrued interest on secured debenture	30,000
Accrued other	122,173	45,631
Total	$ 660,023	$ 468,756

XML 49 R38.htm IDEA: XBRL DOCUMENT

PATENT ACQUISITION OBLIGATION (Details) - USD ($)		3 Months Ended		6 Months Ended
PATENT ACQUISITION OBLIGATION (Details) - USD ($)	Mar. 27, 2017	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Oct. 31, 2016
PATENT ACQUISITION OBLIGATION (Details) [Line Items]
Patent Acquisition Obligation						$ 4,171,876
Gain (Loss) on Extinguishment of Debt		$ 1,547,608		$ 1,547,608
Meetrix [Member]
PATENT ACQUISITION OBLIGATION (Details) [Line Items]
Patent Acquisition Obligation	$ 4,400,000
Stock Issued During Period, Value, Acquisitions	2,843,000
Gain (Loss) on Extinguishment of Debt	$ 1,548,000
Meetrix [Member] \| Common Stock [Member]
PATENT ACQUISITION OBLIGATION (Details) [Line Items]
Stock Issued During Period, Shares, Acquisitions (in Shares)	947,606

XML 50 R39.htm IDEA: XBRL DOCUMENT

PREFERRED STOCK REDEMPTION (Details) - USD ($)			6 Months Ended
PREFERRED STOCK REDEMPTION (Details) - USD ($)	Dec. 09, 2016	Dec. 06, 2016	Apr. 30, 2017	Nov. 11, 2016
PREFERRED STOCK REDEMPTION (Details) [Line Items]
Preferred Stock, Redemption Amount				$ 3,500,000
Preferred Stock, Redemption Terms		Pursuant to the Series A Redemption Terms, on December 9, 2016 the holder of the Series A Preferred received (i) $500,000 in cash, (ii) a 12% secured debenture evidencing the remaining $3,000,000 amount to be redeemed, $1,000,000 of which is due on or before June 1, 2017 and the remainder of which is due November 11, 2017 (the “Redemption Debenture”), and (iii) a 5 year warrant to purchase 500,000 shares of the Company’s common stock at an exercise price equal to 10% below the thirty (30) day volume weighted average closing price of our common stock at closing (the “Redemption Warrant”).
Payments for Repurchase of Redeemable Convertible Preferred Stock	$ 500,000
Warrant Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	500,000
Warrant Exercise Price Percentage	10.00%
Redemption Debenture Present Value			$ 2,999,000
Preferred Stock Conversion Right Intrinsic Value			792,000
Preferred Holder Consideration Transferred			5,508,000
Redeemable Preferred Stock Dividends			2,008,000
Due On Or Before June 1 2017 [Member]
PREFERRED STOCK REDEMPTION (Details) [Line Items]
Debt Instrument, Face Amount	$ 1,000,000
Redemption Warrant [Member]
PREFERRED STOCK REDEMPTION (Details) [Line Items]
Warrants Not Settleable in Cash, Fair Value Disclosure			$ 2,801,000
Redemption Debenture [Member]
PREFERRED STOCK REDEMPTION (Details) [Line Items]
Secured Debt	$ 3,000,000
Secured Debt [Member]
PREFERRED STOCK REDEMPTION (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.00%

XML 51 R40.htm IDEA: XBRL DOCUMENT

NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) - shares	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Series A Preferred Stock [Member]
NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		739,958		739,958
Employee Stock Option [Member]
NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,153,472	3,138,472	3,155,872	3,138,472
Warrant [Member]
NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	837,400	707,387	837,400	707,387

XML 52 R41.htm IDEA: XBRL DOCUMENT

NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) - Reconciliation between basic weighted average common shares outstanding and dilutive weighted average common shares outstanding - shares	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Reconciliation between basic weighted average common shares outstanding and dilutive weighted average common shares outstanding [Abstract]
Basic weighted average common shares outstanding	9,734,171	8,736,024
Effect of stock options	2,400
Dilutive weighted average common shares outstanding	9,736,571	8,736,024

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 54 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 118 173 1 false 37 0 false 4 false false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://www.ITUScorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.ITUScorp.com/role/ConsolidatedBalanceSheet CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.ITUScorp.com/role/ConsolidatedBalanceSheet_Parentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://www.ITUScorp.com/role/ConsolidatedIncomeStatement CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parentheticals) Sheet http://www.ITUScorp.com/role/ConsolidatedIncomeStatement_Parentheticals CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) Sheet http://www.ITUScorp.com/role/ShareholdersEquityType2or3 CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) Statements 6 false false R7.htm 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.ITUScorp.com/role/ConsolidatedCashFlow CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 007 - Disclosure - BUSINESS AND FUNDING Sheet http://www.ITUScorp.com/role/BUSINESSANDFUNDING BUSINESS AND FUNDING Notes 8 false false R9.htm 008 - Disclosure - STOCK BASED COMPENSATION Sheet http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATION STOCK BASED COMPENSATION Notes 9 false false R10.htm 009 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.ITUScorp.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 10 false false R11.htm 010 - Disclosure - INVESTMENTS Sheet http://www.ITUScorp.com/role/INVESTMENTS INVESTMENTS Notes 11 false false R12.htm 011 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://www.ITUScorp.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 12 false false R13.htm 012 - Disclosure - PATENT ACQUISITION OBLIGATION Sheet http://www.ITUScorp.com/role/PATENTACQUISITIONOBLIGATION PATENT ACQUISITION OBLIGATION Notes 13 false false R14.htm 013 - Disclosure - PREFERRED STOCK REDEMPTION Sheet http://www.ITUScorp.com/role/PREFERREDSTOCKREDEMPTION PREFERRED STOCK REDEMPTION Notes 14 false false R15.htm 014 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK Sheet http://www.ITUScorp.com/role/NETINCOMELOSSPERSHAREOFCOMMONSTOCK NET INCOME (LOSS) PER SHARE OF COMMON STOCK Notes 15 false false R16.htm 015 - Disclosure - EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS Sheet http://www.ITUScorp.com/role/EFFECTOFRECENTLYADOPTEDANDISSUEDPRONOUNCEMENTS EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS Notes 16 false false R17.htm 016 - Disclosure - INCOME TAXES Sheet http://www.ITUScorp.com/role/INCOMETAXES INCOME TAXES Notes 17 false false R18.htm 017 - Disclosure - COMMITMENT AND CONTINGENCES Sheet http://www.ITUScorp.com/role/COMMITMENTANDCONTINGENCES COMMITMENT AND CONTINGENCES Notes 18 false false R19.htm 018 - Disclosure - BUSINESS AND FUNDING (Tables) Sheet http://www.ITUScorp.com/role/BUSINESSANDFUNDINGTables BUSINESS AND FUNDING (Tables) Tables http://www.ITUScorp.com/role/BUSINESSANDFUNDING 19 false false R20.htm 019 - Disclosure - STOCK BASED COMPENSATION (Tables) Sheet http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables STOCK BASED COMPENSATION (Tables) Tables http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATION 20 false false R21.htm 020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.ITUScorp.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.ITUScorp.com/role/FAIRVALUEMEASUREMENTS 21 false false R22.htm 021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://www.ITUScorp.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://www.ITUScorp.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES 22 false false R23.htm 022 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Tables) Sheet http://www.ITUScorp.com/role/NETINCOMELOSSPERSHAREOFCOMMONSTOCKTables NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Tables) Tables http://www.ITUScorp.com/role/NETINCOMELOSSPERSHAREOFCOMMONSTOCK 23 false false R24.htm 023 - Disclosure - BUSINESS AND FUNDING (Details) Sheet http://www.ITUScorp.com/role/BUSINESSANDFUNDINGDetails BUSINESS AND FUNDING (Details) Details http://www.ITUScorp.com/role/BUSINESSANDFUNDINGTables 24 false false R25.htm 024 - Disclosure - BUSINESS AND FUNDING (Details) - Significant balance sheet amounts affected by the offering Sheet http://www.ITUScorp.com/role/SignificantbalancesheetamountsaffectedbytheofferingTable BUSINESS AND FUNDING (Details) - Significant balance sheet amounts affected by the offering Details http://www.ITUScorp.com/role/BUSINESSANDFUNDINGTables 25 false false R26.htm 025 - Disclosure - STOCK BASED COMPENSATION (Details) Sheet http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONDetails STOCK BASED COMPENSATION (Details) Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 26 false false R27.htm 026 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding the 2003 Share Plan Sheet http://www.ITUScorp.com/role/Informationregardingthe2003SharePlanTable STOCK BASED COMPENSATION (Details) - Information regarding the 2003 Share Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 27 false false R28.htm 027 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under 2003 share plan Sheet http://www.ITUScorp.com/role/Stockoptionsoutstandingandexercisableunder2003shareplanTable STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under 2003 share plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 28 false false R29.htm 028 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding the 2010 Share Plan Sheet http://www.ITUScorp.com/role/Informationregardingthe2010SharePlanTable STOCK BASED COMPENSATION (Details) - Information regarding the 2010 Share Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 29 false false R30.htm 029 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding under 2010 Share Plan Sheet http://www.ITUScorp.com/role/Stockoptionsoutstandingunder2010SharePlanTable STOCK BASED COMPENSATION (Details) - Stock options outstanding under 2010 Share Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 30 false false R31.htm 030 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding Stock options granted not under 2003 Share Plan and 2010 Share Plan Sheet http://www.ITUScorp.com/role/InformationregardingStockoptionsgrantednotunder2003SharePlanand2010SharePlanTable STOCK BASED COMPENSATION (Details) - Information regarding Stock options granted not under 2003 Share Plan and 2010 Share Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 31 false false R32.htm 031 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding not under 2003 Share Plan and 2010 Share Plan Sheet http://www.ITUScorp.com/role/Stockoptionsoutstandingnotunder2003SharePlanand2010SharePlanTable STOCK BASED COMPENSATION (Details) - Stock options outstanding not under 2003 Share Plan and 2010 Share Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 32 false false R33.htm 032 - Disclosure - FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value Sheet http://www.ITUScorp.com/role/HierarchyforfinancialassetsmeasuredatfairvalueTable FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value Details http://www.ITUScorp.com/role/FAIRVALUEMEASUREMENTSTables 33 false false R34.htm 033 - Disclosure - FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value Sheet http://www.ITUScorp.com/role/HierarchyforfinancialliabilitiesmeasuredatfairvalueTable FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value Details http://www.ITUScorp.com/role/FAIRVALUEMEASUREMENTSTables 34 false false R35.htm 034 - Disclosure - FAIR VALUE MEASUREMENTS (Details) - Changes in the fair value of the Company's Level 3 financial liabilities measured at fair value Sheet http://www.ITUScorp.com/role/ChangesinthefairvalueoftheCompanysLevel3financialliabilitiesmeasuredatfairvalueTable FAIR VALUE MEASUREMENTS (Details) - Changes in the fair value of the Company's Level 3 financial liabilities measured at fair value Details http://www.ITUScorp.com/role/FAIRVALUEMEASUREMENTSTables 35 false false R36.htm 035 - Disclosure - INVESTMENTS (Details) Sheet http://www.ITUScorp.com/role/INVESTMENTSDetails INVESTMENTS (Details) Details http://www.ITUScorp.com/role/INVESTMENTS 36 false false R37.htm 036 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense Sheet http://www.ITUScorp.com/role/AccountspayableandaccruedexpenseTable ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense Details http://www.ITUScorp.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables 37 false false R38.htm 037 - Disclosure - PATENT ACQUISITION OBLIGATION (Details) Sheet http://www.ITUScorp.com/role/PATENTACQUISITIONOBLIGATIONDetails PATENT ACQUISITION OBLIGATION (Details) Details http://www.ITUScorp.com/role/PATENTACQUISITIONOBLIGATION 38 false false R39.htm 038 - Disclosure - PREFERRED STOCK REDEMPTION (Details) Sheet http://www.ITUScorp.com/role/PREFERREDSTOCKREDEMPTIONDetails PREFERRED STOCK REDEMPTION (Details) Details http://www.ITUScorp.com/role/PREFERREDSTOCKREDEMPTION 39 false false R40.htm 039 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) Sheet http://www.ITUScorp.com/role/NETINCOMELOSSPERSHAREOFCOMMONSTOCKDetails NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) Details http://www.ITUScorp.com/role/NETINCOMELOSSPERSHAREOFCOMMONSTOCKTables 40 false false R41.htm 040 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) - Reconciliation between basic weighted average common shares outstanding and dilutive weighted average common shares outstanding Sheet http://www.ITUScorp.com/role/ReconciliationbetweenbasicweightedaveragecommonsharesoutstandinganddilutiveweightedaveragecommonsharesoutstandingTable NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) - Reconciliation between basic weighted average common shares outstanding and dilutive weighted average common shares outstanding Details http://www.ITUScorp.com/role/NETINCOMELOSSPERSHAREOFCOMMONSTOCKTables 41 false false All Reports Book All Reports itus-20170430.xml itus-20170430.xsd itus-20170430_cal.xml itus-20170430_def.xml itus-20170430_lab.xml itus-20170430_pre.xml true true ZIP 59 0001513162-17-000168-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001513162-17-000168-xbrl.zip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�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end

ITUS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

	(Unaudited)
	April 30, 2017		October 31, 2016
ASSETS	April 30, 2017		October 31, 2016
Current assets:
Cash and cash equivalents	$	2,876,897	$	2,488,323
Short-term investments in certificates of deposit		2,250,000		750,000
Prepaid expenses and other current assets		64,647		162,069
Total current assets		5,191,544		3,400,392

Patents, net of accumulated amortization of $1,127,688 and $965,040, respectively		1,908,423		2,071,071
Property and equipment, net of accumulated depreciation of $68,228 and $46,950, respectively		149,487		156,644
Total assets	$	7,249,454	$	5,628,107

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	660,023	$	468,756
Secured debenture (Note 7)		3,000,000		-
Total current liabilities		3,660,023		468,756

Patent acquisition obligation		-		4,171,876
Total liabilities		3,660,023		4,640,632

Commitments and contingencies (Note 11)

Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding		-		-
Series A convertible preferred stock, par value $100 per share; 140 shares authorized; -0- and 140 shares issued and outstanding, respectively		-		14,000
Common stock, par value $.01 per share; 24,000,000 shares authorized; 11,694,863 and 8,752,387 shares issued and outstanding, respectively		116,949		87,524
Additional paid-in capital		156,066,446		152,051,144
Accumulated deficit		(152,593,964)		(151,165,193)
Total shareholders’ equity		3,589,431		987,475

Total liabilities and shareholders’ equity	$	7,249,454	$	5,628,107

The accompanying notes are an integral part of these condensed consolidated financial statements.